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It was recently discovered that IgG, the predominant immunoglobulin in cervicovaginal mucus 
(CVM) secretions in humans, can trap otherwise readily diffusive viruses in CVM by crosslinking virions 
to mucins. Despite forming only weak and transient interactions with mucins, Herpes Simplex Virus-
binding (HSV) IgG immobilized HSV in human CVM with sub-neutralizing potency. Importantly, vaginal 
delivery of non-neutralizing anti-HSV-1 IgG protected mice against vaginal HSV challenge, and the 
protection was lost when vaginal mucus was removed. These results underscore that virus-binding IgG 
can work in tandem with CVM to block infections, and provided the first blueprint for reinforcing the 
mucus membrane against pathogens. Although promising, it was unclear whether IgG-mucin 
crosslinking can be consistently harnessed to enable protection against STIs across diverse women over 
time. A large body of literature has correlated the biochemical and mechanical (rheological) properties 
of mucus to factors such as the menstrual cycle, exogenous hormones, and the vaginal microbiota. Here,  
I investigated how the menstrual cycle as well as microbial and biochemical variations of CVM may 
impact the potencies of IgG-mucin interactions. Given the variations in the structure and effector 
functions of different antibody isotypes, I then identified the monoclonal antibody isotype most potent 
for trapping virions in CVM. Finally, I investigated whether IgG-mucin cross-linking can be observed at 
other mucosal surfaces and be effective in immobilizing even highly motile bacterial pathogens. 
Altogether, my findings strongly underscore IgG-mucin crosslinking to be a universal effector function of 
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CHAPTER 1: INTRODUCTION 
 
1.1 IgG-mediated trapping as a novel mucosal effector mechanism 
 
A critical function of polymeric matrices in biological systems, including mucus and other highly 
glycosylated extracellular matrix components such as laminin and collagen, is to exert selective control 
over the transport of diverse species such as ions, proteins, and cells, while simultaneously limiting the 
passage of infectious pathogens.1,2 This implies that nature should have evolved conserved biochemical 
features that can tune the barrier properties of biological matrices with molecular specificity. There is 
considerable interest in reinforcing the diffusional barrier properties of mucus against infections, 
particularly since blocking transmissions at the portal of entry minimizes the risks of systemic spread of 
infections.3  Slowing or immobilizing pathogens in mucus may not only reduce the pathogen load 
reaching target cells in the epithelium4 and facilitate elimination by natural clearance mucus 
mechanisms, but also facilitate inactivation by innate and adaptive immune factors.5 Together, these 
functions offer the potential to block initial infections altogether.6   
More antibodies (Abs) are secreted into mucus than either the blood or lymph.7–10 Despite their 
abundance in mucus, the use of Abs to reinforce the diffusional barrier properties of mucus was long 
overlooked.11,12  Due to their high specificity against unique pathogen types, Abs represent an ideal 
platform to tune the barrier properties of mucus gels with molecular specificity.13  The key conundrum 
was their seemingly negligible affinity to mucins. Indeed, a study by Olmsted et.al. determined the 
diffusion coefficients of IgG and IgA antibodies (Abs) in human mucus to be ~5–10% lower compared to 
in buffer, whereas larger viruses diffused through mucus unhindered.14,15 The slightly retarded diffusion 
of both IgA and IgG implied they must be slowed by weak and transient interactions with the mucus 
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gel.8,13–15  However, the dogma was that such weak IgG-mucin affinity cannot crosslink pathogens to the 
mucin mesh. The key conceptual breakthrough came when researchers began exploring whether 
polyvalent IgG-mucin bonds can effectively crosslink pathogens to mucins. Wang et.al. showed that HSV-
binding IgG effectively immobilized herpes simplex virus type 1 (HSV-1) in human CVM, even at sub-
neutralizing IgG concentrations.6  By excluding HSV-1 from diffusing through mucus and contacting the 
vaginal epithelium, IgG-mediated trapping of HSV-1 directly prevented vaginal herpes transmission in 
mice. The protection was abolished when vaginal mucus was removed, validating that virus-specific IgG 
worked in tandem with mucus to reduce infection.6 Similarly, in mouse CVM, anti-polyethylene glycol 
(PEG) IgG and IgM effectively trapped otherwise mucus-penetrating PEGylated nanoparticles, and 
restricted the particles to only the most luminal mucus layer of the mouse vagina, even when delivered 
in a hypotonic buffer solution.4 Finally, a cocktail of Ebola-binding IgG Abs (ZMapp) effectively reduced 
the mobility of Ebola virus-like particles in undiluted human lung airway mucus (AM) secretions and 
facilitated rapid elimination the viral particles from the mouse airways following pulmonary delivery of 
the ZMapp.16 These findings strongly support the ability for Abs, either secreted by the immune system 
or topically delivered to mucosal surfaces, to reinforce the mucosal barrier against foreign pathogens. 
 
1.2 Questions unknown: Exploring the universal nature of IgG-mucin crosslinking 
 
Passive immunization with pre-selected Abs has several advantages over the active 
immunization approach; administration of pre-engineered Abs, optimized against a particular pathogen, 
resolves concerns regarding inter-individual immune responses after active immunization,17–19 time lag 
in development of a humoral immune response,20,21 and the uncertainty of how long protective Ab titers 
will persist.11,22 However, the properties of Ab that maximize trapping in mucus (muco-trapping), as well 
as the properties of the mucus that support Ab-mediated trapping of pathogens in mucus, remain 
poorly understood. The trapping potency of IgG is naturally affected by its binding and unbinding rates 
to mucins.7,8,13 Given the variability in fragment crystallizable (Fc) structure and glycosylation among Abs 
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which can in turn modulate Ab-mucin affinity, identification of the most potent Ab isotype in mediating 
virus trapping in CVM is an important step in enabling effective passive immunization of mucosal 
surfaces. Moreover, in order for this muco-trapping effector function to protect against vaginal 
infections, it is essential that this mechanism of vaginal immunity is conserved not only across the 
menstrual cycle, but also among women possessing different microbiota.11,23 Finally, it remains unknown 
whether Abs are capable of retarding the mobility of highly motile pathogens, such as Salmonella, as 
well as block pathogen permeation at other mucosal surfaces (e.g. gastrointestinal mucus, GIM).  
 
1.3 Thesis overview  
In this thesis, my goal is to provide evidence that this novel “muco-trapping” effector function of IgG is 
universally conserved across distinct mucosal surfaces and pathogen types. This goal is divided into the 
following three aims: 
Aim 1: Characterize the biological and chemical features of cervicovaginal mucus that 
compromise or reinforce Ab-mediated trapping of virions. CVM is populated by a microbial community, 
and its viscoelastic and barrier properties can vary substantially not only across the menstrual cycle, but 
also in women with distinct microbiota. How these variations impact the “muco-trapping” effector 
function of IgGs remains poorly understood. Here we obtained multiple fresh, undiluted CVM specimens 
(n = 82 unique specimens) from six women over time, and employed high-resolution multiple particle 
tracking to quantify the mobility of fluorescent Herpes Simplex Viruses (HSV-1) in CVM treated with 
different HSV-1-binding IgG. The IgG trapping potency was then correlated to the menstrual cycle, and 
the vaginal microbial composition was determined by 16s rRNA. 
Aim 2: Investigate muco-trapping potency of different Ab subclasses (IgG1-IgG4, IgA1, IgA2.).  
It remains poorly understood which IgG subclass, and which Ab isotype (IgG vs. IgA), can most potently 
enable Ab-mediated trapping of viruses in CVM. Here, we produced and characterized six monoclonal 
antibodies (mAbs; IgG1-IgG4 as well as IgA1 and IgA2) all possessing identical fragment antibody-binding 
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(Fab) domains that bind glycoprotein D (gD) on Herpes Simplex Virus type 1 (HSV-1), and used high 
resolution multiple particle tracking to quantify their ability to immobilize fluorescently labeled HSV-1 
virions in fresh, undiluted CVM.   
Aim 3: Evaluate the effectiveness of Ab-mucin interactions in blocking highly motile Salmonella 
Typhimurium in mouse gastrointestinal mucus (mGIM). The GI mucosa is coated with a continuously 
secreted mucus layer that serves as the first line of defense against invading enteric bacteria. We 
previously showed that antigen-specific IgG can immobilize viruses in both human airway and genital 
mucus secretions through multiple low-affinity bonds between the array of virion-bound IgG and 
mucins, thereby facilitating their rapid elimination from mucosal surfaces and preventing mucosal 
transmission. Nevertheless, it remains unclear whether weak IgG-mucin crosslinks could reinforce the 
mucus barrier against the permeation of bacteria driven by active flagella beating, or in predominantly 
MUC2 mucus gel.  Here, we performed high resolution multiple particle tracking to capture the real time 
motion of hundreds of individual fluorescent Salmonella typhimurium in fresh, undiluted GI mucus from 
Rag1–/– mice, and analyzed the motion using a hidden Markov model framework.   
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CHAPTER 2: MUCUS AS A PROTECTIVE BARRIER TO INFECTION 
 
 
2.1 Biochemistry of mucus 
 
Mucus is a hydrogel that serves as the first line of defense against pathogens at epithelial 
surfaces throughout the body.24–26  It is both a physical and biochemical barrier, excluding the passage of 
deleterious bacteria and viruses,2,27,28 while simultaneously allowing passage of small molecules.29 
Mucus protects the body from mechanical stress of the food we swallow and provides lubrication during 
coitus,30,31 functions as a reservoir for billions of resident microbial flora bacteria,32,33 and contains 
bioactive molecules such as antimicrobial peptides (AMPs),34 defensins,35 and secreted antibodies to 
maintain tissue homeostasis.36–38  
While mucus is composed of approximately 95% water, it’s barrier properties are conferred in 
large part by glycoproteins called mucins, accounting for 1-5% of mucus mass.24,39 Structural features of 
mucins include: (i) a central protein core, composed largely of serine, threonine, and proline repeats,2,40 
(ii) regions of dense, O-linked glycosylation,39,41 including acidic sugars or sulfate-containing groups, 
which provide an overall negative charge to mucins under most pH conditions , and (iii) hydrophobic 
naked protein domains (Figure 2.1).40,42,43 The charged nature of mucin sugars allows them to serve as 
binding sites or energy sources for both healthy and harmful pathogens.44 As a result of their high 
carbohydrate content (70-80% by weight),42,44 mucins greatly expand upon hydration,27 conferring 
functional properties to the mucus gel such as pathogen exclusion, rheological and hydrational 
dynamicity, lubrication, and bioactivity (Table 2.1).2,29,39 Glycosylation, length, and structure of mucins 
may vary across different mucosal surfaces in the body,39,45 with further structural diversity introduced 
by inflammatory or disease states of the epithelium,44,46,47 and microbial composition.48,49 The 
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nonglycosylated domains of mucin glycoproteins exhibit rich chemical diversity; charged, hydrophobic, 
or thiolated domains, can engage in intermolecular or intramolecular interactions to influence the 
rigidity and crosslinking of mucins in the polymeric mesh.50,51 
Mucins are divided into two classes on the basis of their biological function: secreted or 
membrane-associated mucins. The secreted mucin class consists of gel-forming mucins, which form 
viscoelastic gels that confer the rheological properties of bulk mucus and serve as the first line of 
defense against pathogens.31,40 Membrane-associated mucins are an essential part of the cell-surface 
glycocalyx, involved in an array of interactions between the cell and external environment.24,25,39   
 
2.2 Mechanisms of pathogen breach of the mucosal barrier 
 
To colonize mucosal surfaces and cause pathology, microbes typically must first penetrate the 
secreted mucus barrier to reach the epithelium.25,41 Opportunistic pathogens employ a wide variety of 
subversion strategies to circumvent mucosal defenses.52,53 For example, partial to complete degradation 
of mucin molecules is often a fundamental step in microbe colonization of the mucosal barrier.24,44 
Hence, hydrolyzing enzymes capable of degrading mucin core proteins (mucinases) or carbohydrates are 
produced by a broad range of bacterial pathogens.29,44,54 While glycosylated regions of mucins are 
relatively resistant to proteolytic degradation, non-glycosylated regions are less so.29 Proteolytic 
cleavage of the polymeric mucin network leads to reduced viscoelasticity and disruption of gel 
structure,29,54 resulting in greater infiltration by foreign pathogens.44,54 
Negatively charged carboxyl groups on terminal sialic acid residues and sulfate groups in N-
acetylglucosamine and galactose sugars promote ionic interactions between carbohydrates and the core 
peptide, inducing a stiff and extended conformation.39,44 Degradative enzymes that recognize glycan 
structures and their linkages are synthesized by microbes to yield monosaccharides as an energy 
source,44,54 reveal specific patterns of underlying sugars that serve as adhesion sites for colonization,55,56 
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or disrupt the rheological properties of mucus.24,25,29 Examples of these include sulfatases, sialidases, and 
N-acetyl neuraminate lyases.33,42,44  
Another mechanism used by bacteria to establish at mucosal surfaces is the expression of 
‘adhesins’ to bind mucin or cell-surface oligosaccharides.25,41 Adhesins act as receptors for specific 
carbohydrates on mucins to facilitate entrapment within the mucus and attachment to underlying 
epithelial cells.1,55,57  Influenza viruses, adenoviruses, and coronaviruses all bind to sialic acid-containing 
carbohydrates, present both at the epithelial surface and highly expressed in mucins.42,58 In bacteria, 
lectins (i.e. carbohydrate-binding proteins), are one of the most extensively studied classes of 
adhesins.54,59 Outer membrane proteins, cell wall components (e.g. lipopolysaccharide (LPS)), and 
bacterial pili may also function as adhesins.42,60  Successful adhesion stimulates expression of virulence 
genes and invasive pathogen proteins, such as those required for secretion systems.42,54,61 Importantly, 
based on their ability to be shed from the cell surface, one of the main functions of cell-associated 
mucins is to release decoy glycan ligands to prevent microbes from engaging with the cell surface.40,41  
Of note, epithelial cell adherence is exhibited both by invasive and non-pathogenic micro-organisms.41,57 
For some, this may be a truly commensal relationship;25,57 For others, adhesion is a necessary step in 
initiating pathogenesis.33,63  
Viruses are capable of rapid transport in mucus, conferred by essential surface properties that 
allow them to  avoid mucoadhesion;14  virus capsids are densely coated with both positive and 
negatively charged groups, creating a hydrophilic and neutral to near-neutral shell that effectively 
minimizes electrostatic interactions with mucus64,65. Bacteria are larger than mucus pores28,65 and cannot 
effectively permeate mucus by Brownian motion alone. Hence, many bacteria evolved actively beating 
flagella, a key virulence factor for many bacterial pathogens.66,67 Flagella are capable of rotating in 
excess of 15,000 rpm66 to propel bacteria towards favorable environments to access nutrients or 
facilitate breakthrough of the mucus barrier.24,67–69 Several studies have shown that aflagellated mutants 
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of bacteria are less invasive than their wild-type counterparts.67,68,70 Mechanisms of bacterial access to 
the epithelium are illustrated in Figure 2.2.41  
 
2.3 Mucosal Immunity in the Female Reproductive Tract  
2.3.1 Biology and immune defenses of the female reproductive tract 
 
The female reproductive tract (FRT) consists of two unique types of mucosal surfaces; the upper 
portion, comprised of the endocervix and endometrium, is lined by a monolayer of columnar epithelial 
cells with tight junctions, while the lower portion, the ectocervix and vagina, is lined with stratified 
squamous epithelial cells.12,23 Composed of only a single layer of cells, the ‘cervical transformation zone,’  
the boundary where endo- and ectocervix meet, is particularly vulnerable to pathogen invasion.12,71,72 As 
a result, this area is the most immunologically active site in the FRT, and densely populated with T cells, 
macrophages, and antigen presenting cells.71,73 Nevertheless, the squamous epithelium of the vagina is 
the primary area to come into contact with seminal fluid containing potentially infectious virions; hence, 
this large surface area arguably presents an even greater number of sites for pathogen entry than the 
cervical transformation zone.12,23,71  
The extensive functions of the FRT, including: support of reproductive success and copulation, 
embryonic development, menstrual regulation, and defense against environmental insults while 
simultaneously sustaining a commensal microbial population, dynamically influence mucosal 
immunity.73,74 Each organ in the FRT (fallopian tubes, uterus, cervix, vagina) responds independently to 
changes in hormone levels throughout the menstrual cycle in a manner synchronized with reproductive 
function, and to meet the challenges in protecting against sexually transmitted infections (STIs).23,71 The 
immune system of the FRT consists of both innate and adaptive components, both of which are 
regulated by the cyclic production of estradiol and progesterone.75,76 These hormones influence the 
migration of specific immune effector cells, alter the secretion of cytokines, chemokines, and 
antimicrobials, and promote the expression of pro-inflammatory mediators by epithelial cells.77,78 The 
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term “window of vulnerability,” has been used to describe a period beginning around day 12 of a normal 
menstrual cycle and ending around day 21.23  During this time, mucus viscosity is lowered to permit 
sperm penetration, which can also enhance pathogen invasiveness.79,80  
The physical epithelial barrier, mucus, acidic pH in the lower reproductive tract, complement, 
antimicrobial functions of innate immune cells, and select commensal bacteria together comprise the 
primary components of innate immunity in the FRT. 75,81,82 While the multilayered structure of epithelial 
cells in the lower FRT helps to prevent against bacterial and viral and challenge,75 disruption of tight 
junctions or damage to squamous epithelial cells may enhance susceptibility to infection.23,83 An integral 
part of the innate and adaptive immune systems, epithelial cells secrete antimicrobial factors to directly 
kill invading microbes, as well as cytokines and chemokines to recruit and activate a full spectrum of 
immune cells from the submucosa when pathogenic challenge exceeds their protective capacity.12,75,77 
Cytokines, such as TNFa, IL-8 and TGF-beta, play a significant role in activating tissue-resident 
macrophages and dendritic cells (DCs).12,75 Neutrophils, present throughout the FRT, express toll-like 
receptors (TLRs) 1-9, with broad specificity for viral and bacterial molecular patterns.12,75  TLR activation 
of neutrophils results in phagocytosis, production of oxidative compounds, and release of AMPS such as 
defensins, protease inhibitors, and phospholipases.34,75   
Type I interferons (IFNs) are an especially important class of cytokines in FRT immunity, 
particularly against viruses.12 Innate, cellular, and humoral immunity, including DC maturation and 
natural killer (NK) cell activation, are induced by IFNg to recruit circulating B and T cells to the vagina.73  
DCs process and present viral and bacterial antigens (Ag) to naïve B and T lymphocytes, bridging innate 
to adaptive immunity. Ag presentation to naïve T cells in vaginal draining lymph nodes leads to effective 
priming of virus-specific CD4+ and CD8+ T cells.12,73 CD4+ T cells are sub-divided into Th1, Th2, and Th17 
cells, each displaying unique mucosal defenses; Th1 cells can destroy intracellular pathogens, while Th2 
cells promote humoral responses to control extracellular pathogens. Th17 cells promote further 
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neutrophil activation and AMP secretion by epithelial cells.72,84 In addition to naïve T cells, DCs prime 
naïve B cells to secrete Ag-specific antibodies (Abs).75 These Abs promote antibody-dependent cell-
mediated cytotoxicity (ADCC), phagocytosis, or pathogen elimination through the complement 
system.84,85  In general, the distribution of immune cells and immune functions are specific to each site 
in the FRT, illustrated by Figure 2.3.12,86   
Mucus coating the lower genital tract forms an approximate 50 µm thick layer,8,87 and is 
comprised primarily of secreted mucin type 5 (MUC5B).45,88 It functions as a physical and biochemical 
barrier to protect the underlying epithelium of the vagina, as well as the upper tract from ascending 
infections,73,75 and is rich in immunoglobulins (IgA and IgG).11,12  However, in contrast to other mucosal 
sites throughout the body where IgA is abundant,38 Ag-specific antibodies in the vagina are 
predominantly IgG,37,89 transported from systemic circulation to the apical surface of the vagina via 
neonatal Fc receptor (FcRn) present on vaginal epithelial cells is responsible for transcytosis of IgG from 
systemic circulation to the apical surface of the vagina.90 Reduced levels of IgA in the vagina may be 
partially due to the lack of lack luminal secretory IgA and mucosa-associated lymphoid tissues (MALT) 
compared to in the endocervix and endometrium.11,73  Importantly, immunoglobulin-secreting B cells are 
abundant in the endocervix, but found in limited numbers in the vagina, supporting the importance of 
FcRn-mediated transport of IgG from the bloodstream to the vaginal mucosa.84,90  As expected, IgG 
levels in CVM are modulated throughout the menstrual cycle in response to reproductive hormones, 
found in lower concentration at midcycle when the mucosa is primed for sperm penetration, relative to 
the late proliferative phase.23,75  
 
2.3.2 The vaginal microbiome and risk factors for sexually transmitted infections 
 
The microbial population in the vaginal mucus layer consists of commensal populations of 
bacteria and fungi, with Lactobacillus being the primary species of bacteria associated with a healthy 
vaginal microbiome.32,47 Lactobacilli contribute to FRT immunity by providing non-specific biochemical 
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defenses against a broad range of pathogens.47,71 These bacteria produce pH-modulating lactic acid (LA)  
to acidify the vaginal microenvironment, as well as hydrogen peroxide and other antimicrobials to 
create a neutralizing barrier against colonization by harmful bacterial strains or viruses.32,91 Despite its 
importance in protection of the vaginal mucosa, the influence of the vaginal microbiota on immune 
responses to sexually transmitted viruses remains unclear.92,93 As with other components of the 
defensive barrier in the FRT, endogenous sex hormones and hormonal contraceptives can alter the 
composition of resident vaginal microbes.46,94,95 
To gain insight into the means by which vaginal microbiome ecology influences the barrier 
properties of the female reproductive tract, Ravel et.al. used 16s rRNA sequencing to profile the 
microbiota of CVM from nearly 400 asymptomatic, non-pregnant women.32 They identified five unique 
clusters of microbiota, which were termed ‘community state types’ (CSTs). Of these, four were 
predominated by Lactobacillus species, while the fifth had lower proportions of LA-producing bacteria, 
and higher proportions of strict anaerobes (Figure 2.4).96  Groups were distinguished by the particular 
Lactobacillus species present, if at all (CST-I: L. crispatus, CST-II: L. gasseri, CST-III: L. iners, and CST-V: L. 
jensenii).  In good agreement with reports that Lactobacilli are important to mucosal protective 
immunity in the FRT,72,97 Lactobacillus species were present in 73% of CVM samples.32 L. crispatus (CST I) 
dominated microbiota of 26% of women tested, with CVM pH levels ranging from 3.5-4.5.47 L. iners (CST 
III) predominated in 34% of samples, and was the most prevalent among the Lactobacillus-dominated 
CSTs. Interestingly, while CST IV was not dominated by Lactobacillus spp., L.iners and L.crispatus were 
detected in 79% and 52% of group IV, respectively,32 emphasizing the importance of LA secretion in 
vaginal mucosal protection.72   
Vaginal microbial communities are continuously exposed to disturbances such as antibiotics,48 
hormonal contraceptives,46,72 sexual activity, or intrinsic factors of innate and adaptive immune 
defense.98 As a result, disruption of the vaginal ecosystem, reflected in alterations to the composition 
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and structure of these communities, is almost inevitable. Dysbiosis in vaginal microbial communities, as 
observed with bacterial vaginosis (BV), may increase susceptibility to sexually transmitted infections 
including HIV, herpes simplex virus (HSV) and human papillomaviruses (HPV) by approximately two-
fold.48,72,92  To analyze the resilience and resistance to change of microbial communities in the FRT,  
Gajer et.al. collected CVM samples from 32 women over a 16-week period and analyzed the bacterial 
composition by 16s rRNA gene sequencing.92 While menstrual cycle and sexual activity were associated 
with lack of microbial stability over short periods of time, the stability of vaginal communities was 
largely associated with the dominant species of Lactobacilli.72,92  L.crispatus (CST I) dominated 
communities were most likely to transition to L.iners (CST III), but least likely to undergo transition to 
other CSTs in general. L.iners is frequently associated with moderately elevated pH levels compared to 
L.crispatus dominated specimens (pH > 4.5), and frequently observed in women with recurring episodes 
of BV (CST IV).47,48 Interestingly, CST IV often transitioned to L.iners CST III, but rarely to CST I. 
Significantly, L.iners-dominant communities were twice as likely to transition to CST type IV-B, which 
consisted largely of Gardnerella and other BV-associated taxa including Prevotella.48,98 Prevotella 
positively affects the growth of G.vaginalis, through production of key nutrients such as amino acids and 
ammonia.32  
The biophysical and diffusional barrier properties of mucus are directly influenced by the vaginal 
microbiota.46,97  As the numbers of LA-producing bacteria or bacterial diversity are decreased,54,99 and 
numbers of strict anaerobes is increased, risk of infection is also increased.99,100 For instance, we have 
shown that, unlike CVM from women with L. crispatus, CVM from women with L.iners and G.vaginalis-
dominated microbiota were less likely to immobilize HIV virions at native pH,97 supporting research that 
links these vaginal microbial communities to increased risk of acquiring HIV.48,99 One possible 
mechanism to explain these observations is the secretion of sialidase enzymes by G.vaginalis, which 
cleave sialic acid sugars from mucins to yield markedly reduced mucus viscoelasticity. In addition, due to 
13 
its pro-inflammatory nature, BV can increase the number of viral target cells in the epithelium, further 
enhancing the risk of sexually transmitted infection.101   
 
2.3.3 Challenges in immunization against sexually transmitted viruses 
 
Global estimates suggest more than one million STIs are acquired every day, with sexually active 
individuals between the ages of 15 to 25 years old being at highest risk.102,103 The Center for Disease 
Control and Prevention (CDC) estimates ~20 million new STIs per year in the United States, accounting 
for a medical cost burden of $16 billion.102  Genital herpes, caused by both HSV-1 and HSV-2,104 affects 
an estimated 560 million people aged 14-49 worldwide, with more than 50 million cases in the U.S. 
alone.102,103 Infection is lifelong, and spectrum of disease can range from asymptomatic to ulcerative 
disease with active viral shedding.102,105  Due to greater biological susceptibility, women and adolescent 
girls are more severely impacted by STIs than men.105,106  One of the greatest public health 
consequences of STIs is their role in enhancing HIV-1 transmission;103,107 HSV infection increases the risk 
of HIV-1 transmission by two to three-fold.103,108,109 Despite numerous efforts, Gardasilä and Cervarixä, 
preventing oncogenic strains of HPV, are the only currently licensed vaccines against a sexually 
transmitted virus.108,110   
The development of preventative mucosal vaccines is precluded by several challenges.110–112  
Firstly, vaccine development must take into account the unique characteristics and interdependent 
relationships of the FRT mucosa, including the microbiome and sex hormones.76,91,113,114 Although 
dysbiosis of vaginal ecology has been shown to increase viral replication and shedding,91,93 few studies 
have evaluated the association between vaginal microbial communities and successful vaccination.72,110  
Even less is known about the impact of reproductive hormones on vaccine responses in humans.11,115  
Immune responses regulated by sex hormones in the FRT include Ag presentation, cytokine production, 
and immunoglobulin production and transport.115  Improved methods to study the efficacy of mucosal 
vaccination should therefore integrate data on the impact of both the microbiome and hormone 
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status.107  Secondly, an appreciation of FRT anatomy and differences in innate and adaptive cell subsets 
that shape mucosal immunity are important determinants for effective vaccine design11,108. For example, 
protective immunity against HIV and HSV must elicit both B and T cell responses at the site of 
infection;108,110 however, in the absence of inflammation or infection, the FRT restricts the entry of 
activated T-cells.72  Finally, cell-mediated protection against invasive pathogens is dependent upon the 
specific immune cells found within the local mucosal environment. Distinct DC subsets in the FRT play 
different roles in the generation of protective immunity.110  In the cervicovaginal mucosa, monocytes, 
macrophages and neutrophils are the predominant Fc receptor (FcR) bearing cells.116  While relatively 
abundant, these cells are localized beneath the epithelium, potentially limiting the timely engagement 
of specific antibodies with FcR-bearing cells in vaginal tissue to prevent initial viral invasion.116,117 
Consequently, vaccines that rely on cellular immunity alone to prevent STIs have been unsuccessful.72,86   
Where and how a vaccine against an STI needs to be delivered to generate robust, long-lasting, 
and tissue-specific immunity in the female genital tract remains a yet unanswered question.11,110  
Reliable animal models and well-validated functional assays recapitulating immune responses induced 
by natural infections in humans are still lacking,118,119 limiting the capacity to define effective clinical trial 
endpoints.107 Further, vaccine components and adjuvant selection can influence the signals that induce 
immune cell homing to specific sites in the genital mucosa.112,119,120 Moreover, while vaginal, intranasal, 
and sublingual immunizations may  elicit adequate genital mucosal immune responses, the intranasal, 
oral and rectal routes have been less successful.11,120  Thus, vaccine design against STIs must take into 
account the route of immunization, as well as the nature vaccine  components themselves.110,120  
 
2.4  Immunity of the gastrointestinal tract  
 
2.4.1 Immunobiology of the gastrointestinal mucosa 
 
Like the FRT, the GI mucosa (beyond the stomach) is coated with a continuously secreted mucus 
layer, primarily composed of MUC2 secreted by goblet cells.24,121  GI mucus (GIM) varies in thickness 
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from 100 μm to 800 μm, increasing from the duodenum to the distal colon.122  The small intestine 
harbors a single mucus layer that is continuously sloughed off with peristaltic motion,2,123 while mucus in 
the colon exists in two layers with distinct rheological and barrier properties.39,83  The insoluble inner 
layer is firmly attached to the epithelium, providing a physical barrier to protect underlying cells from 
direct contact with commensal microbes and pathogenic insults.63,124  The outer, loose layer extends to 
the luminal surface, and is home to the largest community of commensal microbes in the body, which 
increase in diversity and number descending distally.27,39,41  The GIM contains a diverse array of 
immunoglobulins, defensins, and AMPs that serve as the first line of defense in protection against 
invasive pathogens.27,41   
Despite the growing recognition of the mucus barrier in regulating the severity of infectious 
diseases,82,125–127 further investigation of how bacterial pathogens interact with mucus components is 
needed to enhance the development of successful therapeutic strategies. As the largest mucosal surface 
in the body, the gut mucosal immune system faces a constant battle between eliminating potential 
pathogens and maintaining homeostasis with commensals.128,129 An abundance of antibodies, 
particularly secretory IgA (sIgA), are secreted into GIM to maintain this mutually beneficial 
relationship.38,124  SIgA coats intestinal microbes to block them from attaching to, colonizing, and 
invading the mucosal epithelium,122,130 and guides bacterial entry into intestinal lymphoid tissues, where 
tolerogenic, Ag-specific IgA is produced in a positive feedback loop.122 In turn, microbiota-specific sIgA 
promotes host-microbiota mutualism by reducing the inflammatory response to commensals.131 The 
ability of sIgA to agglutinate (crosslink) pathogens together through its recognition of polyvalent Ags on 
bacterial and viral surfaces, termed ‘immune exclusion’ is perhaps the most commonly proposed 
mechanism of sIgA-mediated protection in mucus.128,130 SIgA-induced agglutination leads to reduced 
diffusion of bacterial aggregates, which are too large to permeate GIM.70 Entrapment in the mucus gel 
promotes bacterial clearance via gut peristalsis.132   
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Adaptive immunity in the GI mucosa is mediated by gut-associated lymphoid tissues 
(GALT),131,133 characterized by a complex network of cellular and molecular components which confer 
the capacity to differentiate harmless commensal bacteria from pattern associated molecular patterns 
(PAMPs) on enteric pathogens.22 Aggregates of lymphoid follicles in the GALT (known as Peyer’s patches, 
PPs) are enriched with B cells whose differentiation is driven in response to specific Ags present in the 
intestinal lumen. Overlying these organized lymphoid follicles, the ‘follicle-associated epithelium’ (FAE), 
contains a distinctive class of epithelial cells called M cells.126,134 These cells are specialized for the 
uptake and trans-epithelial transport of intact microorganisms or soluble Ags to immune cells in the 
lamina propria.128  Presentation of foreign Ags to DCs and macrophages in the PP is supported by the 
absence of MUC2 on the M cell surface;22 Consequently, M cells are more accessible to particles, viruses, 
and bacteria than adjacent enterocytes.128  
 
2.4.2 Global burden of Salmonella infection  
 
The presence of the mucus layer has necessitated the evolution of specific virulence strategies 
to allow enteric pathogens to cross the mucus layer and reach the epithelium.27,41 Salmonella use 
flagellum-based motility to penetrate the mucus layer,67,70 and defends itself against antimicrobial 
compounds in mucus by altering gene expression, reducing permeability of its outer membrane, and 
activating extracellular scavenging pathways.22,128 Peyer’s patches are a portal of entry for Salmonella, 
which specifically target M cells.135  As facultative intracellular pathogens, Salmonella can survive both 
extracellularly and intracellularly, presenting a significant challenge in development of an effective 
vaccine: humoral immunity is key for dealing with extracellular bacteria, while intracellular bacteria are 
typically eliminated through cellular mechanisms of CD4+ and CD8+ T cells.135,136  The tolerogenic nature 
of the GI tract poses an additional challenge; successful methods of protection must induce specific 
activation of the immune system against Salmonella, whilst avoiding potentially adverse effects that 
disrupt gut homeostasis.22  
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Salmonella are responsible for a significant global disease burden, with consumption of 
contaminated food and water being a leading cause of morbidity and mortality worldwide.70,136  In 
developing countries, children under the age of five are especially susceptible to infections caused by 
Salmonella, which presents in two forms: enteric fever and invasive nontyphoidal Salmonella (iNTS) 
disease.52,136 It is estimated that more than half a million deaths and 16 million cases of typhoid fever 
each year are caused by Salmonella enterica serovar Typhi (S.Typhi) alone.128 Immunocompromised 
individuals, such as malaria and HIV-infected patients, are particularly susceptible to infection, which 
predominantly manifests as iNTS with bacteremia.52 In children, fatality is estimated to be between 20-
25%, and up to 47% in HIV-infected adults.136,137  The high prevalence of Salmonella-associated 
morbidity, together with an increased emergence of multidrug-resistant strains,52,136,137 has prompted 
development of novel vaccination strategies. The two currently available systemic vaccines against 
Salmonella have major limitations;22,136 both the live attenuated and Vi capsular polysaccharide vaccines 
are targeted against S.Typhi, with limited cross-protection among three key invasive serovars: Paratyphi 
A, Typhimurium and Enteritidis. Moreover, both are poorly immunogenic in young children, and neither 
are licensed for use in children under two years old.22,136 Hence, new strategies to protect against 
Salmonella, particularly in at-risk cohorts, can have an enormous impact on global health.   
 
2.4.3 Antibody-mediated protection against Salmonella 
 
Due to their target specificity and ability to be optimally engineered to induce specific arms of 
protective immunity, monoclonal antibodies (mAbs) are a highly effective class of biotherapeutics.138,139 
While typically administered via parenteral routes due to their instability in the GI tract, oral 
administration of mAbs may be an effective tool to prevent enterobacterial infection.140–142 The most 
critical factor influencing successful oral passive immunization of the gut is delivery of sufficient 
quantities of active Ab, which can be influenced by gastric pH, protease activity, and GI residence 
time.140  Abs are gradually inactivated and degraded when exposed to gastric proteolytic enzymes such 
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as pepsin and elastase.140,142 To overcome these unfavorable biochemical conditions, researchers are 
developing oral deliver formulations that preserve therapeutic mAb bioactivity.140,141,143  
Antibodies are essential factors in mediating protection against invasive Salmonella.144–146 
Passive transfer studies with both IgA and IgG subclasses, and targeted against a number of bacterial Ags 
including flagella, outer membrane proteins, and LPS have been shown to limit pathogen invasiveness 
by several mechanisms: facilitating uptake and killing of Salmonella by phagocytes,137,147 reducing 
bacterial adhesion to epithelial cells,148 and altering outer membrane integrity.149 Nevertheless, given 
that Salmonella must penetrate GIM to reach and infect the host epithelium,24,125,150 limiting mucus 
penetration should provide an effective way to prevent and/or treat infections. Several studies have 
shown that IgA is capable of arresting bacterial motility.70,149 Impairment of Salmonella motility 
attenuates disease and reduces bacterial invasiveness,70,151,152 as non-motile mutants of S. Typhimurium 
are 30–50 fold less invasive than their parental wild type strains.56,67,68  
 
2.5 Relevance of Ab subclasses in infectious disease 
 
An Ab’s functional protective capacity is modulated through biophysical and biochemical 
differences in the Fc region, including Ab isotype, subclass, and heavy chain glycosylation (Figure 2.5). 
85,119,153 IgG and IgA isotypes can be divided into six subclasses (IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) 
with unique structural features and response profiles to different infectious diseases due to their 
variable affinity for Fc-receptors (FcRs).118,119,139 Ab functionality is further tuned through alterations in 
Fc-domain glycans, or specific glycosylation sites within each isotype.154  Glycan modifications impact Ab 
stability, half-life, and the flexibility of the Fc domain to allow differential interaction with FcRs.118,119,155 
There are 36 possible glycan structures in the IgG subclass alone (Figure 2.6).118,119  
Due to its extended hinge region, which increases its flexibility and binding affinity to all FcRs, 
IgG3 is believed to have the greatest functional potency among the IgG subclasses. Nevertheless, this 
extended hinge region is highly vulnerable to proteolytic degradation; hence, IgG3 has a circulation half-
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life of only seven days compared to the 21-day circulation time of IgG1.118,156,157  Considered the next 
most potent IgG, IgG1 also binds all FcRs.119,156 By contrast, IgG2 and IgG4 are less functional, owing to 
limited ability to activate complement,118,157 reduced affinity for most FcRs,119 and overall lower 
abundance in human serum.116 Like IgG3, IgA1 has an extended hinge region that renders it more 
susceptible to proteolytic cleavage compared to IgA2,158,159 typically found in higher concentrations at 
mucosal membranes than IgA1.157 
Ab effector functions include direct pathogen capture and neutralization, ADCC, phagocytosis of 
Ab-coated pathogens, or induction of antibody-dependent phagocytosis (ADCP) to engage innate 
immune cells to clear infected host cells.116,153,160 FcRs, both activating and inhibitory, are expressed on a 
wide range of innate immune cells (Figure 2.7).85,119,153 However, given the varied distribution of innate 
immune cells in different tissues, the functional activity of Abs is highly dependent upon the availability 
of each effector cell type at the site of pathogen transmission or replication.86   
Ab subclass responses in natural infection can be highly skewed with respect to isotype and 
subclass depending on the nature of the pathogen, including whether it is intra- or extracellular, virus, or 
bacteria.160 In humans, the immune system naturally selects for an IgG1/IgG3 response to viral 
infection,116,153 but a dominant IgG2 response to polysaccharides following bacterial infection.119,160 
Interestingly, subclass responses can differ for distinct Ags on the same pathogen, or even different 
domains within an antigen.118,161 Further, Ab subclass is likely to depend on epitope density, and the 
flexibility of different subclasses to interact with those epitopes.118,162 Moreover, unique Ab responses 
are induced by distinct vaccines, driving differential consequences for antiviral or antibacterial 
activity.116,119,120,163 Understanding Ab characteristics (i.e. isotype, subclass, glycosylation) in the context 
of natural infection, vaccination, and influence on pathogen control, may provide novel insights to 
augment vaccine or therapeutic mAb functionality through selective induction of particular Ab effector 
mechanisms of action, while avoiding unwanted responses.118,119
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Figure 2.1:  Structure of mucin glycoproteins reproduced from Bansil et.al.39 
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Figure 2.2: Mechanisms of bacterial breach of the mucosal barrier.41  
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Figure 2.4: Heatmap of proportions of microbial taxa found in the vaginal bacterial communities of 
reproductive aged women. (A) Linkage clustering based on species composition and abundance. (B) 






Figure 2.5: Antibody isotypes and subclasses. Domains include an antigen-binding fragment (Fab) and a 
crystallizable fragment (Fc) domain that binds to host sensors to deploy effector functions. Each 
molecule is composed of four chains with two identical heavy chains (blue) and two identical light chains 
(red), further divided into variable (VH or VL) and constant (CH or CL) domains. Secretory component is a 
proteolytic cleavage product of the polymeric immunoglobulin receptor that remains associated with 













CHAPTER 3: HERPES SIMPLEX VIRUS BINDING IgG TRAPS HSV IN HUMAN CERVICOVAGINAL MUCUS 





Mucus that coats the vaginal epithelium is primarily secreted by goblet cells in the cervix, which 
flows out of the cervical os by gravitational and/or intra-abdominal pressure driven flow 1, 2; we call this 
cervicovaginal mucus (CVM) to reflect its physiological origins. CVM serves not only as a lubricant that 
reduces shear-induced damage to the vaginal epithelium during coitus, but also as a physical barrier that 
excludes pathogens in semen from immediately contacting the epithelium following ejaculation 3, 4. In 
addition, CVM harbors a broad array of AMPs and proteins, including immunoglobulins, that comprise 
the innate and adaptive mucosal immune defense against sexually transmitted pathogens 3, 4, 5. Thus, 
slowing or immobilizing viruses in CVM can not only directly reduce the pathogen load reaching target 
cells in the epithelium and facilitate elimination from the vagina by mucus flow to external genitalia, but 
also allow for more complete inactivation by innate and adaptive immune factors. Together, these 
functions offer the potential to block initial infections altogether. 
There is considerable interest in reinforcing the diffusional barrier properties of mucus against 
infections, particularly since blocking transmissions at the portal of entry minimizes the risks of systemic 
spread of infections. Despite the abundance of IgG in CVM 6, 7, the use of IgG to reinforce the diffusional 
                                                        
1 This chapter is based on an article that previously appeared in the Mucosal Immunology. The original 
citation is as follows: Schroeder HA, Nunn KL, Schaefer A, Henry CE, Lam F, Pauly MH, Whaley KJ, Zeitlin 
L, Humphrys MS, Ravel J, Lai SK. Mucosal Immunol. 2018 Sep;11(5):1477-1486. HAS contributed to 
experimental design, completed experiments, performed data analysis, and wrote the paper.  
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barrier properties of CVM against pathogens was long overlooked, due to the seemingly negligible 
affinity between individual IgG molecules and mucins 8, 9, 10, 11.  Indeed, diffusion of IgG in human mid-
cycle endocervical mucus is only slowed ~10% compared to in buffer 12, 13 , implying the affinity is so 
weak that most individual IgG remains unbound to mucins at any moment in time. Nevertheless, 
multiple IgG can accumulate on the same virion or bacteria and confer substantial binding avidity 
between mucins or other mucus constituents and IgG-pathogen complexes akin to a Velcro patch with 
individually weak hooks.  We have shown that Herpes-specific IgG can effectively trap individual Herpes 
Simplex Viruses (HSV-1) in CVM at sub-neutralizing concentrations via multiple transient Fc-mucin bonds 
14. Importantly, trapping HSV in mucus alone appears to offer effective protection against vaginal Herpes 
transmission in vivo by excluding trapped particles from contacting the vaginal epithelium 11, 14.  
The ability of virus-specific IgG to trap virions in mucus is undoubtedly influenced by the rigidity 
and microstructure of the mucin mesh network, as well as the interactions between IgG and mucins.  A 
large body of literature has correlated the biochemical characteristics and mechanical (rheological) 
properties of mucus to factors such as the menstrual cycle15, 16, 17 exogenous hormones17, 18  and the 
vaginal microbiota 19, 20. Indeed, the dense community of commensal microbiota that populate CVM not 
only varies considerably between women as well as within the same woman over time, but also directly 
impacts the biophysical properties of CVM as well as its diffusional barrier properties against viruses 21, 
22, 23. For instance, G. vaginalis, the predominant microbe in BV, can secrete sialidase enzymes that 
cleave sialic acid sugars from mucins, leading to a marked loss in mucus viscoelasticity20, 24, 25, and is 
associated with an elevated risk for acquiring sexually transmitted infections (STIs). The innate 
diffusional barrier properties of CVM against HIV were previously shown to correlate to the vaginal 
microbiota 19, 21, 26.   
 In order for this muco-trapping effector function to protection against vaginal infections, it is 
essential that this mechanism of vaginal immunity is conserved not only across the menstrual cycle, but 
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also among women possessing different microbiota 6, 27. To test the breadth and consistency of this 
trapping function, we collected fresh and undiluted CVM secretions from six women with different 
microbiota and contraceptive use across their menstrual cycle, and employed high resolution multiple 
particle tracking to quantify the diffusion rates of hundreds of individual fluorescent HSV-1 virions in 
CVM treated with different antibodies (Abs). We found the barrier properties of CVM against HSV to be 
consistently reinforced by the presence of HSV-specific IgG in CVM.  
 
3.2 Results  
3.2.1 Exogenous polyclonal and monoclonal antibodies against Herpes Simplex Virus Type I (HSV-1) 
effectively trap HSV-1 in CVM.  
In a previous study with seven CVM specimens from unique donors, we showed that 
exogenously added polyclonal antibodies (pAb) against HSV-1, purified from intravenous 
immunoglobulin, effectively trapped virions in pH-neutralized mucus even at sub-neutralizing levels. In 
contrast, HSV readily penetrated the same CVM specimens in the absence of HSV-specific antibodies 14. 
We first sought to replicate our original finding that exogenously added anti-HSV-1 pAb would similarly 
trap HSV-1 in CVM. We mixed HSV-1 virions expressing a VP22-GFP (green fluorescent protein) 
tegument protein construct, packaged at high copy numbers while maintaining native viral envelope 
integrity (d~180nm) into undiluted, pH-neutralized CVM treated with different Ab, and performed 
multiple particle tracking to quantify the mobility of hundreds of individual viruses in each condition.  
In 82 CVM specimens collected from six donors, the addition of anti-HSV-1 pAb to a final 
concentration of 5 µg/mL in CVM decreased the ensemble average effective diffusivities (<Deff>) for 
HSV-1 by ~10-fold compared to anti-biotin IgG control, in good agreement with our previous 
observations (Fig 1) 14. There is substantial heterogeneity in the mobility of individual virions, particularly 
in native, untreated CVM; the same CVM specimen frequently contains both freely diffusing and 
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immobilized virions 14, 21, 26. Virions that possess the greatest diffusivity (i.e. the most mobile fractions) 
by definition are more likely to diffuse across the mucus layer and infect the underlying epithelium 
before mucus is purged by natural clearance mechanisms. Thus, we sought to assess the effect of 
exogenous anti-HSV-1 pAb in limiting the fraction of HSV-1 that could most readily penetrate CVM. We 
quantitatively defined the fast-moving subpopulation as virions that possess sufficient mobility to 
penetrate through a physiologically thick CVM layer (50µm) in one hour, which yielded a minimum Deff ≥ 
0.347 µm2/s 9, 26, 28. The addition of anti-HSV-1 pAb reduced the fraction of fast-moving virions by ~10-
fold, from 33.4% ± 15.5% to 3.4 ± 4.5%.  In a subset of these 82 samples, we evaluated the effectiveness 
of trapping at lower pAb concentrations in a subset of CVM specimens (n=26, Fig 2A-B).  The average 
<Deff> decreased ~3- and ~4-fold in CVM containing 0.5 and 1 µg/mL anti-HSV-1 pAb compared to anti-
biotin IgG control (p<0.01**). This translated into a decrease in the fraction of “fast-moving” virions 
from 30.2 ± 13.4% to 14.4 ± 9.9% and 11.6 ± 11.6%, respectively (p<0.0001****).  
Since monoclonal antibodies (mAb) are far easier and cheaper to manufacture and characterize 
than pAb, we next investigated whether mAb against HSV-1 gD could immobilize the virions in CVM 
similarly to pAb 29. We produced two variants of the same anti-gD IgG1 mAb, one in mammalian cells 
(HSV8-293), and the other in tobacco plants i.e., Nicotiana benthamiana, engineered with human 
glycosylation pathways (HSV8-N) 30.  We were able to directly compare the trapping potency of all three 
Ab in the same CVM specimen in 70 of the 82 CVM specimens collected.  In general, both mAb were 
slightly less effective at trapping HSV-1 than pAb, with <Deff> of 0.0057 ± 0.005 µm2/s, 0.0065 ± 0.0065 
µm2/s and 0.004 ± 0.003 µm2/s in HSV8-293, HSV8-N and pAb treated CVM (final concentration 5 
µg/mL).  The fast-moving populations were reduced from 32.3% in untreated CVM to 7.5 ± 6.3%, 8.2 ± 
6.6% and 2.7 ± 3.4% for HSV8-293, HSV8-N and pAb, respectively (Fig 2C-D). These results underscore 
the potential of using mAb to reinforce the diffusional barrier of CVM against specific pathogens.  
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3.2.2 Ab-Mediated Trapping Appears to be Independent of Menstrual Cycle Phase and Consistent Across 
the Menstrual Cycle  
Properties of cervical mucus, such as mucus thickness and viscoelasticity, vary substantially 
across the menstrual cycle in response to hormonal changes18, 27. Because CVM originates primarily from 
cervical mucus rather than secretion by the vaginal epithelium, it is essential to investigate whether pAb 
and mAb can effectively trap viruses in both luteal and follicular phase CVM. To examine this, we 
stratified the data from the n=70 specimens into either follicular or luteal phase, based on the day of the 
menstrual cycle when each sample was collected. We included CVM from women on hormonal birth 
control in this analysis, as many current hormonal contraceptives phase the level of hormone exposure 
throughout the treatment cycle, and a significant proportion of women still display ovarian activity and 
follicular development. Given it is more likely that women on hormonal contraceptive will engage in 
unprotected intercourse, it is critical for us to assess whether the effectiveness of IgG-mediated trapping 
of viruses is conserved over time in women with hormonal contraceptives31, 32.  Since none of the 
samples we collected displayed spinnbarkeit, the egg-white like stretchy mucus that is hallmark of 
ovulatory mucus, we excluded further stratifying the data into a third mid-cycle phase. While the 
potency of pAb was slightly greater relative to mAbs in the luteal phase (n=38) compared to follicular 
phase (n=32) samples, Ab-mediated trapping by mAbs was consistent across both phases, and there 
were no statistically significant differences in ensemble-averaged <Deff> or percent of fast-moving virions 
between the two mAb formats.  Interestingly, the average Deff in the anti-biotin IgG condition was 
approximately 50% lower in the luteal phase compared to follicular phase (0.027 ±  0.023 µm2/sec vs. 
0.057 ±  0.06 µm2/sec, ****p<0.0001), possibly due to cervical mucus thickening in response to 
increased progesterone secretion (Fig 3) 16, 18, 19.  
We further investigated whether the trapping potency of pAb and mAb was consistent not only 
between two key phases of the menstrual cycle, but also across the 28-day cycle. We plotted the 
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percent of fast-moving virions and <Deff> as a function of cycle day, and tested for linearity using 
Pearson’s Correlation. Similar to above there was a statistically significant trend in the anti-biotin 
condition that suggests viruses were somewhat less mobile toward the end of the menstrual cycle than 
the beginning (**p<0.01). There was no statistically significant dependence of <Deff> and fraction of fast-
moving virions on cycle day for the various anti-HSV-1 Ab (Fig S1). Likewise, there were no statistically 
significant differences in the consistency of trapping potency between normally cycling donors and 
those taking birth control. Although the number of donors in our study was limited by our capacity to 
follow a larger group of women across several menstrual cycles, the results here are consistent with the 
notion that Ab-mediated trapping potency is likely independent of reproductive hormone levels in the 
female reproductive tract.  
 
3.2.3 Ab-Mediated Trapping Potency of HSV-1 in CVM Appears to be Independent of Vaginal Community  
 
State Type  
 
The vaginal microbiota composition is associated with susceptibility to a diverse array of sexually 
transmitted infections, including herpes and HIV25. Therefore, we were interested in how diverse vaginal 
microbiota may influence IgG-mediated trapping potency for monoclonal and polyclonal IgGs.  We were 
able to characterize the microbial communities in 66 CVM specimens using 16s rRNA gene sequencing, 
and classified them into five community state types (CSTs) 23. The majority of CVM specimens were 
classified as either CST I (L. crispatus-dominated, n=18), CST III (L. iners-dominated, n=22) and CST IV (G. 
vaginalis-dominated, n=16), with a lower prevalence of CST II (L. gasseri-dominated, n=4) and CST V (L. 
jensenii-dominated, n=6), in good agreement with previous findings (Fig S2, Table S1) 23.  
            Despite variations in the native CVM barrier to reduce virion mobility across CSTs, all Ab were 
able to effectively reduce the fraction of fast-moving virions across all CSTs (Fig S3). The addition of 5 
µg/mL pAb to CVM reduced the fraction of fast-moving virions to 1.8% ± 2.4%, 0.8% ± 0.6%, 2.7% ± 
2.2%, 4.1% ± 4.8%, 5.7% ± 4.2% for CSTs I to V, respectively, compared to 28.4% ± 11.5%, 20.0% ± 
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19.8%, 37.3% ± 17.1%, 38.5% ± 14.9% and 31.5% ± 17.3% for untreated CVM from CSTs I to V.  Although 
slightly less potent than pAb, mAbs yielded similarly statistically significant decreases both in the 
ensemble averaged <Deff> and fraction of fast-moving virions. There were no statistically significant 
differences in the trapping potency of either pAb or mAb between CSTs (Fig 4).  
We further investigated the variations in IgG-mediated trapping of HSV within individual donors.  
Donors 21, 43, 57, 58 had relatively consistent microbiota profiles across the time frame assessed, 
whereas donors 36 and 50 presented more dynamic and often changing microbiota (Fig 5). Despite 
differences in birth control status and fluctuations in microbiota, the various anti-HSV-1 Abs consistently 
enabled effective trapping of HSV-1 in all six donors, and there were no statistically significant 
differences in the ability of Abs to slow virions between individuals (Fig 5, Fig S4). Even in CVM with 
nearly 100% of the microbiota represented by G. vaginalis (donor F57), the fraction of fast-moving 
virions was substantially reduced from 38.1% ± 9.1% in untreated control to 3.4% ± 4.5%, 10.9% ± 7.0% 
and 11.8% ± 6.4% when treated with pAb, mAb-293 and mAb-N, respectively (p<0.0001***). This is 
comparable to L. crispatus (CST I) dominant microbiota (F21), where the fraction of fast-moving virions 
was reduced from 28.8 ± 15.1% to 2.6% ± 2.8% by pAb, 5.4% ± 4.0% by HSV8-293, and 5.2% ± 4.3% by 
HSV8-N (p <0.0001****). There was no statistically significant difference in virion mobility in the 
presence of HSV-specific IgG between these CSTs (Fig S3).  
 
3.3 Discussion  
STIs are pandemic worldwide; with the exception of HPV, there are no effective vaccines against 
virtually all common STIs, including Herpes, HIV, Neisseria gonorrhoeae (GC), Chlamydia trachomatis and 
syphilis.  Given the longstanding challenge in eliciting durable immunity against a variety of STIs, some 
investigators are turning to passive immunization of the cervicovaginal environment – whereby 
protective Ab are delivered locally in the female reproductive tract – as a strategy to prevent STI 
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transmission33, 34. In addition to protection by neutralization 35 and other classical effector functions, 
topically dosed Ab can facilitate protection by trapping virions in mucus.  For vaginal transmission, 
viruses must penetrate mucus secretions to reach target cells; indeed, many sexually transmitted 
viruses, including HIV, HSV and HPV, can quickily diffuse and infect their target cells through CVM. 8, 13, 21, 
26  Reinforcing the CVM barrier to trap pathogens in mucus thus represents an obvious strategy to 
prevent STIs. We found here that this unique muco-trapping Ab function is consistently observed both 
across the menstrual cycle as well as in different women with varying microbiota composition. The 
consistency of this muco-trapping function further underscores its likely physiological importance and 
highlights passive immunization of the cervicovaginal environment as a promising strategy to protect 
against diverse STIs.   
 The potential muco-trapping effector function of IgG remains under-recognized, and rarely 
harnessed in the development of prophylaxis against STIs.  Trapping in mucus can protect by directly 
limiting the flux of virions arriving at target cells in the epithelium, facilitating more complete 
inactivation by innate and adaptive immune mechanisms, and enabling more complete elimination by 
natural mucus clearance mechanisms 3. By preventing viruses from reaching target cells, Ab-mucin 
interactions may directly block infections at the portal of entry before initial infections even occur, as 
observed in our mouse Herpes transmission studies 14.  This feature may be especially important against 
STIs that remain difficult to cure or eliminate once infection is established 7. Trapping pathogens in CVM 
is also likely complementary to current prophylactic approaches such as microbicides and PrEP, as 
combining different approaches may lead to synergistically enhanced protection.  Finally, a large 
fraction of trapped virions will be rapidly eliminated via post-coital discharge, which usually occurs 
within minutes, suggesting that a comparable fraction of infectious virions will be cleared from the 
cervicovaginal environment if they are trapped in the discharge.  Trapping virions in CVM is likely to be 
especially important for preventing vaginal HIV, HSV and HPV transmission, since the rate of 
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transmission of these viruses is already quite low 3.  The requirement for many intercourse events 
before a successful transmission event implies that few, if any, infectious virions actually reach target 
cells per intercourse.  Therefore, reducing the fraction of virions that reach target cells will likely lead to 
a proportional reduction in transmission of infection. 
 The native barrier properties of CVM are directly influenced by the vaginal microbiota.  For 
instance, we have shown that, unlike CVM from women with L. crispatus, CVM from women with L. iners 
and G. vaginalis-dominated microbiota, microbiota lacking a significant amount of Lactobacillus species, 
were unable to effectively immobilize HIV at native pH 21. This in turn suggests that women with L. iners 
or G. vaginalis-dominant vaginal microbiota are potentially at greater risks of acquiring HIV, which has 
been confirmed by a number of epidemiological studies for a multitude of STIs 25, 36. It is possible that 
the compromised barrier properties of CVM with dominant L. iners and G. vaginalis reflects a 
breakdown of mucins that could also compromise the ability for virus-bound Ab to crosslink with 
mucins. Indeed, G. vaginalis was thought to increase risks of STI transmission by overexpression of 
sialidases that can cleave terminal sialic acids and break down the mucin matrix of CVM, in addition to 
increasing the number of target cells in the epithelium due to its pro-inflammatory nature 16, 20, 37, 38. 
Encouragingly, we found that both pAb and mAb were able to enhance the barrier properties of CVM 
against HSV across CVM from a diverse spectrum the vaginal microbiota, including G. vaginalis-
dominated vaginal microbiota. These results suggest that harnessing Ab-mucin interactions may help 
reduce STI transmission in women at the greatest risks of acquiring STI 24, 35.   
Cyclic fluctuations in estrogen and progesterone across the menstrual cycle are known to induce 
macroscopic changes in color, consistency, and viscosity of cervical mucus 15, 17, 18; these changes are 
particularly important for enabling or preventing sperm ascension into the upper tract. Nevertheless, 
the potential variations of the barrier properties of CVM as a result of hormone-induced fluctuations of 
CVM remains poorly understood, particularly for barrier properties at the length scale of viruses. Here, 
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we found that independent of the phase of the menstrual cycle and use of hormonal contraceptive, 
HSV-binding Abs were able to specifically reinforce the barrier properties of CVM against HSV-1.  
Importantly, while genital herpes is conventionally associated with HSV-2, HSV-1 actually causes vaginal 
Herpes with comparable frequency, likely due in part to shifts in oral-genital sexual practices39. In 
addition, the two HSV serotypes share significant sequence homology in their protein-coding regions 
(83%), including neutralizing epitopes such as gD (85% sequence homology)39. Indeed, our monoclonal 
Ab binds both HSV-1 and HSV-2, which is the reason why it is currently in clinical trials for vaginal Herpes 
prevention (NCT02579083)40. Further, while the number of donors in our study was limited, we 
speculate that the consistent manner with which we observed Ab-mediated reinforcement of the 
mucosal defense may be an evolutionary trait in humans: unlike most mammals, copulation frequently 
occurs not just during ovulation but across the entire menstrual cycle in humans, necessitating the need 
for protection against STIs beyond the mid-cycle.  
 For translational development, the batch-to-batch nature of pAb preparations is likely too 
expensive and too low throughput to address public health demands 33, 41. Instead, passive immunization 
of the cervicovaginal environment will most likely rely on the scalable and increasingly economical 
processes of mAb production.  Here, we found that the trapping potencies of mAb, regardless of 
whether they were produced in mammalian cells or glycan-modified Nicotiana benthamiana, were 
slightly reduced compared to pAb. This difference is likely attributed to a difference in the number of Ab 
bound to each virion. Compared to mAb that only binds to a specific epitope on the gD glycoprotein, 
pAb purified from whole HSV will include Ab that binds to all major glycoprotein epitopes on the virion 
surface, including gB, gC, gG and gH, and thus achieve greater number of bound Ab than mAb at the 
same Ab concentrations 42. This suggests the slightly lower muco-trapping potency of mAb vs. pAb 
should be readily overcome by targeting epitopes that are present in high numbers on the pathogen 
surface or by simply including multiple different mAbs against the same pathogen.  Indeed, this 
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approach is increasingly utilized in mAb-based antivirals, such as ZMappTM, a formulation of cocktail of 
three distinct mAb against Ebola 43. The use of multiple mAbs targeting different regions of the same 
epitope, or different epitopes on the same virus, would also limit escape mutants of the  
Viruses. 29  
A longstanding challenge that has limited applications of passive immunization is the large dose 
of Ab systemically necessary to facilitate protection at mucosal surfaces, which has translated into 
exceptionally high vaccination costs 44, 45. Nevertheless, a confluence of factors may enable cost-
effective passive immunization of the vagina in the not-too-distant future.  First, passive immunization 
has historically been attempted through systemically administered Ab rather than topical delivery 6, 44.  
Since the female reproductive tract is coated with far smaller volumes of CVM (~1-2 mL) than the 
volume of blood in circulation (~5 L), protective concentrations can thus be readily achieved with far 
lower amounts of Ab by directly delivering locally in the vagina, potentially resulting in cost savings 29, 41, 
45.  Second, advances in drug delivery technologies have made it possible to achieve sustained release of 
Ab from vaginal rings.29 Third, the cost of Ab production has fallen greatly over the past two decades 
due to advances in bioprocessing technology, both in mammalian culture systems and the introduction 
of less common production systems, such as Nicotiana-produced mAb evaluated here.  Large-scale mAb 
production costs were projected at ~$100/g in 2010, and will likely continue to fall in the years ahead 46, 
47.  Since as little as tens of micrograms of mAb per day may be adequate to confer protection, it is 
theoretically possible to achieve passive immunization of the vagina and other mucosal surfaces that are 
cost-effective, particularly for infections that currently lack effective prophylaxis.  Lower costs would 
likely be achieved by further improvements in bioprocessing as well as further optimization of Ab-mucin 
affinity 9.  
The number of specimens and donors we could include in this study is limited by the throughput 
of particle tracking experiments that allow us to capture and quantify the mobility of hundreds of 
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individual virions in each specimen. Unlike most techniques in biology, there are no real-time, objective 
readouts in particle tracking experiments.  Instead, particle tracking involves extensive, careful analysis 
to accurately extract quantitative motion from videos, due to the need to visually inspect and remove 
false positive and false negative traces.  This is particularly true with videos capturing individual viruses 
in biological environments that inevitably suffer from low signal-to-noise contrasts.  Despite these 
limitations, the consistencies of IgG-mediated trapping repeated observed in numerous distinct 
specimens from six women here, and in 11 subjects (each sampled once at a random time point) in our 
earlier study is consistent with the notion that IgG-mucin crosslinking is a broadly conserved effector 
mechanism that is likely consistently observed in women both across the menstrual cycle as well as in 
women with diverse vaginal microbiota.  Our study here motivates further study with a much larger 
cohort. 
 
3.4 Methods and Materials  
3.4.1 CVM collection and characterization 
CVM was collected and characterized as previously described 26. Detailed methods are provided in 
Supplementary Materials and Methods.   
 
3.4.2 Ethics Statement  
 
Written informed consent of participants was obtained after the nature and possible consequences of 
the study were explained. All studies were performed in accordance with a protocol approved by the 
Institutional Review Board of the University of North Carolina at Chapel Hill (IRB 10-1817). 
 
3.4.3 Culture and purification of fluorescent HSV-1  
 
The HSV-1 mutant 166v encoding a VP22-GFP tegument protein packaged into HSV-1 at high copy 
numbers, was kindly provided by Richard Courtney and used in all microscopy and ELISA studies. The 
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addition of GFP to the VP22 protein has no deleterious effects on viral replication, and the fluorescence 
of 166v was consistently more intense than that of HSV-1 mutants encoding other GFP fusion proteins 
48. Virus was expanded at a multiplicity of infection (MOI) of three on confluent monolayers of HaCat 
cells (Addex Biotech, San Diego, CA) maintained in Dulbecco’s modified Eagle’s medium (Life 
Technologies, Grand Island, NY) supplemented with 5% fetal bovine serum, 1X L-glutamine, and 1X 
Penicillin/Streptomycin. Culture medium was collected 16–18 h post infection and centrifuged at 
1,000xg for 5 min to remove cell debris. The resulting supernatant was split into 30-ml aliquots and 
precipitated overnight with a PEG/salt solution. Briefly, 10 ml of 1.55 M NaCl was added to 30 ml of 
crude virus supernatant, followed by 10 ml of 40% PEG 8000 (Sigma, St. Louis, MO). After overnight 
incubation at 4°C, the virus/PEG solution was centrifuged at 2,555xg at 4°C for 1 h. The virus pellet was 
resuspended in 1XPBS (phosphate-buffered saline) and centrifuged through a continuous 20–50% (w/w) 
sucrose in PBS gradient for 1 h at 74,119xg. The resulting virus band was further purified by diluting 1:5 
in PBS, layered over 30% (w/w) sucrose in PBS, and centrifuging for 1.5 h at 83,472xg to pellet. Purified 
virus pellet was resuspended in PBS and stored as single-use aliquots at 80°C. 
 
3.4.4 Preparation and characterization of polyclonal anti-HSV-1 IgG  
 
Polyclonal Anti-HSV-1 IgG was purified from intravenous immunoglobulin (IVIg, Privigen®; ≥ 98% IgG; CSL 
Behring, King of Prussia, PA) by affinity column purification. Detailed methods are provided in 
Supplementary Materials and Methods.    
 
3.4.5 Production of monoclonal HSV8 in 293 cells and Nicotiana benthamiana 
 
HSV8 are produced in Expi293F cells as well as Nicotiana benthamiana as previously described30.  
Detailed methods are provided in the Supplementary Materials and Methods.  
 
3.4.6 Multiple-particle tracking of HSV-1 in CVM 
 
To mimic neutralization of CVM by alkaline seminal fluid, we titrated CVM to pH 6.8–7.2 using 
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small volumes (3% v/v) of 3N NaOH and confirmed pH using a pH microelectrode (Microelectrodes, 
Bedford, NH) calibrated with pH 4, 7, and 10 buffers. Samples were either treated or untreated by the 
addition of known amounts of purified anti-HSV-1 IgG or control (anti-biotin) IgG pre-mixed with 
fluorescent virions (approximately 108–109 particles/mL) and incubated at 37°C for 15-30 minutes prior 
to adding to 20µL CVM in a custom-made glass chamber. Once mixed, Abs, virus, and CVM were 
incubated at 37°C for and additional 15-30 minutes prior to microscopy. Control beads consisted of red 
or green fluorescent 200nm carboxyl-modified PS particles (Molecular Probes, Eugene, OR), either 
uncoated (PS; muco-adhesive) or covalently conjugated with a low molecular weight (2 kDa), amine-
functionalized PEG (Rapp Polymere, Tuebingen, Germany) to produce coated particles (PS-PEG; muco-
inert) as previously described 28. Translational motions of the particles were recorded using an electron 
multiplying charge-coupled-device (EMCCD) camera (Evolve 512; Photometrics, Tucson, AZ) mounted on 
an inverted epifluorescence microscope (AxioObserver D1; Zeiss, Thornwood, NY) equipped with an 
Alpha Plan-Apo 100/1.46 numerical-aperture (NA) objective, an environmental (temperature and CO2)-
control chamber, and light-emitting-diode (LED) light source (Lumencor Light Engine 
DAPI/GFP/543/623/690). Videos (512X512 pixels, 16-bit image depth) were captured with MetaMorph 
imaging software (Molecular Devices, Sunnyvale, CA) at a temporal resolution of 66.7 ms and spatial 
resolution of 10 nm (nominal pixel resolution, 0.156 µm/pixel) for 20 s. The tracking resolution was 
determined by tracking the displacements of particles immobilized with a strong adhesive, following a 
previously described method 49 . Particle trajectories (xy locations) were obtained using Video Spot 
Tracker (VST) developed by Computer-Integrated Systems for Microscopy and Manipulation (CISMM) at 
UNC-CH (http://cismm.cs.unc.edu/downloads). The threshold parameter in VST was set using the Rosin 
threshold algorithm 50, and tracking was monitored and corrected by human intervention. Image 
contrast was adjusted to improve particle visibility, but the same contrast level was applied throughout 
the entire video and did not bias toward any particle population. Subpixel tracking resolution was 
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obtained by determining the precise location of the particle centroid by light-intensity-weighted 
averaging of neighboring pixels. Trajectories were analyzed using “frame-by-frame” weighting 51 in 
which mean squared displacements (MSD) and effective diffusivities (Deff) are first calculated for 
individual particle traces. Averages and distributions are then calculated at each frame based on only 
the particles present in that frame before averaging across all frames in the movie. This approach 
minimizes bias toward faster-moving particle subpopulations. Trajectories of at least 40 particles per 
frame on average were analyzed for each experiment, which typically corresponds to greater than 100 
individual particle traces throughout the video and is consistent with sampling in our previous work14, 21. 
Trapped particles were defined by a Deff value of .0316 µm2/s at a value of 0.2667 s (time scale 
corresponding to a minimum trajectory length of 5 frames); for particles 200 nm in diameter and larger, 
this cutoff translates to particles moving a distance much less than their diameter within 0.2667 s.  
 
3.4.7 16S rRNA sequencing and analysis  
 
DNA extractions for microbiota analysis were performed as previously described22, 23 on aliquots of the 
same CVM samples used for microscopy studies and other characterizations described. The method of 
Fadrosh et al.52 was used to analyze the vaginal microbiota composition and structure and relied on 
amplification and sequencing on an Illumina MiSeq instrument (300-bp paired-end reads) of the V3-to-
V4 regions of the 16S rRNA gene. Sequence analyses and taxonomic assignments were performed using 
a custom pipeline, freely available on GitHub (https://github.com/cwzkevin/MiSeq16S). The resulting 
taxonomic assignments are shown in Table S1. To assess whether the vaginal microbiota affected barrier 
properties and Ab-mediated trapping in CVM, we grouped samples into Community State Types (CSTs) I-
V according to the most dominant bacterial species within a sample. Samples were assigned to CSTs 
according to those identified by Ravel et.al.23: L. crispatus-dominated (CST I), L. gasseri dominated (CST 
II), L. iners-dominated (CST III), a diverse set of strict or facultative anaerobic bacteria such as G. 
vaginalis (CST IV), L. jensenii-dominated (CST V). A sample grouped into a particular CST contained an 
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average of ~80% of the class-defining species (Figure S2). However, microbial populations between 
samples can be extremely diverse. In this sample set, percent of dominant bacterial species used to 
classify CST ranged from 34.26% to 99.9% of total bacteria.   
 
3.4.8 Statistical analysis 
 
Statistical comparisons were performed using ANOVA with multiple comparisons between matched 
samples (Tukey’s multiple comparison’s test) using GraphPad Prism version 7.0 (GraphPad Software, La 
Jolla, CA). Follicular and luteal phases were compared with Two-way ANOVA. Correlation between anti-
HSV-1 IgG mediated trapping and cycle day was measured using Pearson’s correlation coefficient (r). 

















Figure 3.1: HSV-1 mobility as a function of exogenously added polyclonal anti-HSV-1 and or non-
specific anti-biotin IgG control. (A) Sample trace of fast-moving HSV-1 subpopulations, with Deff ≥ 0.347 
µm2/s. (B) Sample trace of trapped virus in CVM. (C) Ensemble-averaged <Deff> and (D) Percent of fast-
moving viruses in CVM treated with 5 µg/mL pAb. Paired two-tailed t-test (*p<0.05, ** p<0.01, 





































































Figure 3.2: HSV-1 mobility in CVM with exogenously added polyclonal anti-HSV-1 IgG (pAb) and 
monoclonal anti-HSV-1-gD. Comparison of IgG produced in Expi293 cells (mAb-293) and Nicotiana 
Benthamiana (mAb-N), and non-specific anti-biotin IgG control. Polyclonal anti-HSV-1 was tested at a 
final concentration of 5, 1, or 0.5 µg/mL. HSV8-293 and HSV8-N mAbs and non-specific anti-biotin IgG 
control tested at 5 µg/mL. (A) Ensemble-averaged <Deff> and (B) percent of fast-moving virions as a 
function of increasing polyclonal anti-HSV-1 concentration. (C) Ensemble-averaged <Deff> and (D) 
percent of fast-moving viruses in CVM treated with mAb-293 and mAb-N vs. pAb. All Ab concentrations 
are 5 µg/mL. Repeated Measures One-Way ANOVA with multiple comparisons (*p<0.05, ** p<0.01, 















































































































































































Figure 3.3: Effect of menstrual cycle phase and birth control status on Ab-mediated trapping of HSV-1 
in pH-neutralized CVM. Six donors were followed across a minimum of two menstrual cycles and 
reported the number of days post-menses; cycles were normalized to 28-days. CVM samples were 
grouped by the cycle phase and separated by birth control status. Samples obtained during the follicular 
phase were those collected 6-14 days post-menses while those collected during the luteal phase were 
from 15-28 days post-menses. At least two samples were collected during the follicular phase and two 
during the luteal phase from each donor. All Abs were tested at 5 µg/mL and compared to anti-biotin 
IgG in matched samples. (A) Average <Deff> of virions in follicular versus luteal phase in NC versus BC 
donors. (B) Percent of fast-moving virions (average <Deff> ≥ 0.347 µm
2/s) by phase in follicular versus 
luteal phase in normally cycling (NC) versus donors on birth control (BC). Data was analyzed using Two-
Way ANOVA with Sidak’s multiple comparisons test. A p ≤ 0.05 was considered statistically significant 







































































Figure 3.4: Ab-mediated trapping of HSV-1 as a function of microbial Community State Type (CST).  
Samples were sequenced with 16s rRNA whole genome sequencing analysis and classified into CSTs 
depending on the predominant microbial species according to the following groups: Class I (L.crispatus, 
n=18), Class II (L.gasseri, n=4), Class III (L.iners, n=22), Class IV (G.vaginalis, n=16), or Class V (L.Jensenii, 
n=6) 23. After classification, HSV-1 mobility was compared for each Ab condition. (A) Ensemble-averaged 
<Deff> in CVM treated with different Ab and (B) Percent fast-moving viruses (Deff) ≥ 0.347 µm
2/s. Two-
Way ANOVA with multiple comparisons [Tukey’s Multiple Comparison’s Test] (*p<0.05, ** p<0.01, 





















































































Figure 3.5: Potency of Ab-mediated trapping in six different individuals across multiple menstrual 
cycles. Donors 50 and 58 were normally cycling (A-F), while donors 21, 36, 43, and 57 were on birth 
control (G-R). Donor samples collected across multiple menstrual cycles were grouped to determine 
whether there was consistency in trapping potency within an individual, based on ensemble-averaged 
<Deff> (A,D,G,J,M,P) and percent of fast-moving viruses (B,E,H,K,N,Q). Donor ID is presented on the left 
side of each set. Heat maps (C,F,I,L,G,R) show the proportion of CST I - CST V out of a total 100% of the 
sequenced microbiome, illustrating the inherent diversity of microbial populations both within an 
individual and across the menstrual cycle. Sample collection days are indicated on the left side of each 
heatmap. Microbes outside of CST I-V were classified as ‘Other’ (O). Heat map scale ranges from 0 
(white) to 100% (black). Data was analyzed using One-Way ANOVA with Tukey’s Multiple Comparison’s 





Figure 3.6 (Supp. Fig1): Ab-mediated trapping potency across the menstrual cycle. Pearson’s 
correlation to test for dependence of HSV-1 mobility on menstrual cycle day (1-28) in each antibody 
condition tested at 5 µg/mL. Statistical significance indicates that the slope of the xy-line is non-zero and 
there is linear dependence in HSV-1 mobility as a function of cycle day. (A/B) Average <Deff> (µm
2/s) and 
percent fast-moving virions (<Deff> ≥ 0.347 µm
2/s) in the presence of anti-biotin IgG, (C/D) Virus mobility 
in the presence of polyclonal anti-HSV-1 IgG, (E/F) HSV-1 mobility in the presence of HSV8-293 mAb; 
(G/H) HSV-1 mobility in the presence of HSV8-N. Alpha of p≤0.05 considered statistically significant. 
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) **p < 0.01
































Figure 3.7 (Supp.Fig.2): Variation in microbiota within individual samples. Sequencing data was used to 
quantitatively determine the predominant microbial population and classify the predominant 
community state type (CST) within each sample according to the following groups established by Ravel 
et.al (31).: CST I (L. crispatus), CST II (L. gasseri), CST III (L. iners), CST IV (G. vaginalis), or CST V (L. 
jensenii). Despite being grouped into a single CST, the majority of samples displayed some level of 
heterogeneity in microbial composition. This figure shows the intra-CST variability within a CST and 
illustrates the uniqueness of the microbiota within an individual CVM sample. Each bar corresponds to a 
distinct sample, and values indicate abundance of different bacterial species as a proportion of all 
species in the sample. Bacteria in “Other” include Lactobacillus helveticus, Lactobacillus vaginalis, 
Ureaplasma parvum, Finegoldia magna, Pediococcus acidilactici, Corynebacterium accolens, Prevotella 
genogroup 2, Peptoniphilus asaccharolyticus, Sneathia sanguinegens, Anaerococcus tetradius, Prevotella 
buccalis, Aerococcus christensenii, Raoultella planticola, Staphylococcus epidermidis, Streptococcus 
agalactiae, Anaerococcus vaginalis, Peptoniphilus harei, Dialister sp. type 1, Atopobium vaginae, 
Peptoniphilus indolicus, Dialister propionicifaciens, Fusobacterium nucleatum, Prevotella bivia, 
Mycoplasma hominis, Streptococcus oralis, Leptotrichia amnionii, Eggerthella, Prevotella disiens, BVAB1, 
Streptococcus salivarius, Staphylococcus hominis, Megasphaera sp. type 1, Peptoniphilus lacrimalis, 
Mycoplasma genitalium, Alloscardovia omnicolens, Staphylococcus aureus, Streptococcus anginosus, 
Veillonella atypical, BVAB2, Escherichia coli, Veillonella parvula, Peptostreptococcus anaerobius, 
Parvimonas micra, Atopobium minutum, Aerococcus viridans, Enterococcus faecalis, Dialister sp. type 3, 
Streptococcus parasanguinis, Varibaculum cambriense, Agrobacterium tumefaciens, Catonella morbi, 
Actinomyces urogenitalis, Enterococcus faecium, Eubacterium saphenum, Howardella ureilytica, 
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Figure 3.8 (Supp.Fig3): Magnitude of change in virion mobility in the presence of HSV-specific IgG by 
donor. Fast-moving (<Deff> ≥ 0.347 µm2/s) HSV-1 virions between in anti-biotin IgG and magnitude of 
reduction in fast-moving populations by HSV-specific Abs. (A) Percent of fast-moving virions in CVM in 
the absence of HSV-specific antibody. (B-D) Percent change in the fast-moving virion population in the 
presence of (A) polyclonal anti-HSV, (B) monoclonal anti-HSV IgG1 produced in HEK293 suspension cells, 
or (C) monoclonal anti-HSV IgG1 produced in tobacco plants. Magnitude of change was calculated by 
subtracting the percent of fast-moving viruses in the HSV-Ab condition from the corresponding value in 
the control Ab (anti-biotin) condition of the same sample. Each data point represents this difference. 
Data was compared using One-Way ANOVA with Tukey’s Multiple Comparison’s test. A p ≤ 0.05 was 


















Figure 3.9 (Supp.Fig.4): Magnitude of change in virion mobility in the presence of HSV-specific IgG by 
CST. Percent fast-moving (<Deff> ≥ 0.347 µm2/s) or effective diffusivity (Deff) of HSV-1 virions between 
control anti-biotin IgG and HSV-specific Abs by community state type. Magnitude of change was 
calculated by subtracting the percent of fast-moving viruses (A-C) or Deff (D-F) in the HSV-Ab condition 
from the corresponding value in the control Ab condition of the same sample. Each data point 
represents this difference. Data was compared using One-Way ANOVA with Tukey’s Multiple 

















































































Figure 3.10 (Supp.Fig.5): D and L-lactic acid quantification by CST. Aliquots of CVM for lactic acid 
measurements were prepared by diluting whole CVM 1:5 (w/w) with PBS. Aliquots were centrifuged for 
2 min at 21,130 g to obtain cell-free supernatant containing lactic acid, which was measured using a D/L-
lactic acid kit (R-Biopharm, Darmstadt, Germany) following the manufacturer’s protocol adapted to a 96-
well format. Lactic acid content is shown as mg/mL (w/v) of CVM. (A) Total lactic acid content by CST; (B) 
D-Lactic acid content by CST; (C) L-Lactic acid content by CST; (D) Ratio of D:L Lactic acid by CST. Data 
were analyzed using One-Way ANOVA with Tukey’s Multiple Comparisons test. A p ≤ 0.05 was 
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3.5 Supplementary Methods and Materials  
3.5.1 CVM collection and characterization 
Briefly, undiluted CVM secretions, averaging 0.3 g per sample, were obtained using a self-sampling 
menstrual collection device (Instead Softcup). Donors inserted the device into the vagina for at least 30 
s, removed it, and placed it into a 50-mL centrifuge tube. Samples (82 CVM specimens collected from six 
donors) were delivered to the laboratory and centrifuged at 200xg for 2 min to collect secretions. The 
menstrual cycle phase was estimated based on the last menstrual period date normalized to a 28-day 
cycle; no samples were ovulatory based on visual observation (none exhibited spinnbarkeit). Samples 
that were non-uniform in color or consistency (less than 1 in 20) were discarded. Since ovarian follicular 
development is not completely suppressed with the use of currently available oral contraceptive 
formulations 1, we normalized cycles to 28 days for both normally cycling individuals (n=2) and 
individuals on birth control (n=4), with day one being the first day of menstruation. Days 6-14 and 15-28 
were considered the follicular and luteal phases, respectively. Donors stated that they had not used 
vaginal products nor participated in unprotected intercourse within 3 days before donating. Donors also 
reported whether they had been using a hormonal contraceptive in the 3 weeks prior to donating. No 
donors reported having had abnormal vaginal symptoms within 7 days prior to donating. The pH of CVM 
samples was measured immediately after sample collection using a pH microelectrodecalibrated to pH 
4, 7, and 10 buffers. The remainder of the sample was stored at 4°C until microscopy, typically within 1 
day of collection. For lactic acid measurements, CVM aliquots were thawed and centrifuged for 2 min at 
21,130xg to obtain cell-free supernatant containing lactic acid, which was measured using a D/L-lactic 
acid kit (R-Biopharm, Darmstadt, Germany) following the manufacturer’s protocol but adapted to a 96-
well format. 
 
3.5.2 Preparation and characterization of polyclonal anti-HSV-1 IgG  
HSV glycoproteins were extracted from purified HSV-1 by overnight incubation with Triton X-100 (final 
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concentration 0.05%) at 4°C, followed by centrifugation at 21,130g at 4°C for 1.5 hr. The  
resulting supernatant containing HSV glycoproteins was coupled to AminoLink Plus Coupling Resins 
(Thermo Scientific, Waltham, MA) according to manufacturer protocol, and stored at 4 °C until use. To 
isolate HSV-1 specific IgG, the column was first warmed to room temperature and washed twice with 3 
mL of equilibrium buffer (150 mM NaCl, 0.05% Tween, 10 mM sodium phosphate at pH 6). The column 
was then loaded with 2 mL of IVIg buffer exchanged into equilibrium buffer using a 50 kDa MWCO 
concentrator (Corning, Tewksbury, MA), and incubated at room temperature for at least 45 min with 
end-over-end mixing. Unbound, non-specific IgG was removed by washing with 1 mL of equilibrium 
buffer followed by three additional rounds of wash buffer (4 mL each round; 500 mM NaCl, 0.05% 
Tween, 10 mM sodium phosphate at pH 6). Bound HSV-specific IgG was then eluted using IgG Elution 
Buffer (Thermo Scientific, Waltham, MA); each elution consisted of three 3 mL volumes of elution 
buffer, and was collected into tubes containing 100 μL of 10 mM sodium phosphate pH 8 to neutralize. 
Elutions were pooled, buffer exchanged into PBS using a 30 kDa MWCO concentrator tube, and re-run 
through the column to ensure that all non-specific IgG was removed. Double-purified elutions were 
pooled, concentrated and buffer exchanged into PBS using a 30 kDa MWCO concentrator tube, 
supplemented with sodium azide (final concentration 0.02%) and stored at 4°C until use. Final 
concentration of purified IgG was measured via sandwich ELISA, with plates coated with 2 μg/mL of anti-
human IgG Fc (Alpha Diagnostics, San Antonio, Tx) followed by detection with F(ab’)2 anti-human IgG Fc 
(Goat)-HRP, and compared to a standard curve generated with serial dilutions of stock IVIg. 
 
3.5.3 Cell culture and transient expression of monoclonal HSV8-293 IgG1 
 
Expi293F™ cells were obtained from Invitrogen (Carlsbad, CA). Expi293F™ Expression Medium and Opti-
MEM® I Reduced-Serum Medium were obtained from Invitrogen. For cell culture and maintenance, 
medium was pre-warmed in a 37 °C water bath. Cells were incubated in a 37 °C incubator with 
humidified atmosphere of 8% CO2 on an orbital shaker platform rotating at 125 rpm in disposable 
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polycarbonate 125mL erlenmeyer flasks from Corning (Tewksbury, MA). Cell culture volume was 
maintained at 30mL. Viable cell density was determined using a hemocytometer and trypan blue. For 
maintenance, cells were grown to a density of 3-5 X 106 viable cells/mL then sub-cultured to 0.3 X 106 
cells/mL, typically every 3–4 days. On the day before transfection, cells were counted and cell viability 
was assessed. Cultures with over 90% viability were seeded at a density of 1.2 × 106 cells/ml 24 hrs prior 
to transfection. Prior to transfection, cells were counted and adjusted to a density of 2.5 X 106 cells/mL. 
Variable regions of the gD glycoprotein for the Ab heavy chain (HC) and light chain (LC) were cloned into 
pFUSE vectors (Invivogen, San Diego, CA) using standard cloning methods. Endotoxin free DNA was 
extracted from transformed bacteria using a Nucleobond xtra Midi Plus EF kit according to 
manufacturer’s protocol (product #740422, Macherey-Nagel, Bethlehem, PA). For each ml of 
transfection volume, 1 μg DNA of high quality, endotoxin free plasmid-DNA from the IgG1 anti-gD heavy 
chain and anti-gD kappa light chain expression plasmids were added to room temperature Optimem at a 
2:3 ratio. DNA was complexed with the 293Fectin mixture. Briefly, DNA and 293Fectin mix were 
complexed over a period of 20-30 minutes, then added to cells dropwise. The transfection proceeded 
for 3-5 days at 125 rpm, 8% CO2 and 37°C. After 24 hours, transfected cells were treated with 
ExpiFectamine 293 Transfection Enhancer according to manufacturer’s protocol (product #A14524, 
Thermo Scientific, Waltham, MA). Cells were monitored for viability and glucose levels over the course 
of transfection. After Ab production, transfection supernatant was collected by spinning down cells for 
10 min at 1000 rpm. The supernatant was then filter sterilized using a 0.22 μM filter and stored at 4 °C 
until purification. Total IgG was purified from Ab supernatant using Pierce Protein A/G agarose 
according to manufacturer’s instructions but adapted to a batch capture method (product #20422; 
Thermo Scientific, Waltham, PA). Elution fractions were buffer exchanged into Dulbecco’ s Phosphate 
Buffer Saline. Ab concentration was quantified by nanodrop (Nanodrop one, Thermo Scientific, 
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Waltham, PA) and verified with a total IgG ELISA. Binding of HSV8-293 Ab was verified with an HSV-
specific ELISA using whole virus using polyclonal anti-HSV as a positive control.  
 
3.5.4 Production of monoclonal HSV8 in 293 cells and Nicotiana benthamiana  
 
For transient expression of the in plants, we used the ‘‘magnifection’’ procedure 2. The mAbs have highly 
homogenous mammalian-type N-glycans via the use of a transgenic strain of N. benthamiana in which 
plant specific glycosyltransferases (α1,3 fucosyltransferase and β1,2 xylosyltransferase) are inhibited by 
siRNA as described previously 3.   Briefly, plants grown for 24-26 days in an enclosed growth room at 22-
24˚C were used for vacuum infiltration.  Equal volumes of overnight-grown Agrobacterium cultures were 
mixed in infiltration buffer (10 mM MES pH 5.5 and 10 mM MgSO4) resulting in a 1:1000 dilution for 
each individual culture.  Using a 300 L custom built vacuum chamber, the aerial parts of entire plants 
were inverted into the bacterial/buffer solution and a vacuum of 22” of mercury was applied for 2 min. 
Seven days post-infiltration, leaf tissue was extracted with a Corenco double stack disintegrator using a 
0.5:1 buffer to plant tissue ratio (extraction buffer: 100 mM Tris, 40 mM ascorbic acid, 1 mM EDTA, pH 
8.5).  The extract was adjusted to pH 8.0 with 10 N NaOH.  Extract was clarified using a plate frame filter-
press (Ertel-Alsop) with 1.0 µm pads. The Ab was captured from the filtrate using a MabSelect SuRe (GE 
Healthcare) Protein A column.  The column was equilibrated and washed with Tris running buffer and 
eluted with acetic acid.  The resulting eluate was neutralized using 1 M Tris.  The mAb solution was then 
further purified via Q filtration (Mustang Q membrane; Pall).  The final polishing column was a CHT, Type 
I 40 µm (Bio-Rad) column.  The column was equilibrated and washed with phosphate running buffer and 
eluted with running buffer containing NaCl. The eluate was neutralized to pH 7.0. The final eluates for 
each Ab were concentrated and diafiltered using tangential flow ultrafiltration with 30KD MWCO cutoff 
polyethersulfone membranes. Mab was sterile filtered, aseptically filled into glass vials with serum 
stoppers, sealed and stored at -80oC. mAbs were fully assembled as determined by SDS-PAGE and had 
less than 5% aggregate as determined by HPLC-SEC. 
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CHAPTER 4: ANTIBODY ISOTYPE VARIATIONS IN POTENCY OF ANTIBODY-MEDIATED IMMOBILIZATION 





For vaginal transmission to occur, viruses must penetrate through cervicovaginal mucus (CVM) 
that coats the female reproductive tract (FRT). We previously showed that monoclonal IgG antibodies 
(mAbs) against the gD glycoprotein on Herpes Simplex Virus type 1 (HSV-1) effectively immobilized 
individual HSV-1 virions in fresh, undiluted CVM6, and that this muco-trapping function of IgG was 
consistently observed across the menstrual cycle as well as in different women with varying microbiota 
composition.164 HSV-1 specific IgG can effectively trap individual HSV-1 virions in CVM at sub-
neutralizing concentrations,6 facilitated by multiple Fc-mucin bonds between mucins or other mucus 
constituents and the array of IgG bound to each virion, akin to a Velcro patch with many individually 
weak hooks.13 Importantly, trapping HSV in mucus alone appears to offer effective protection against 
vaginal Herpes transmission in vivo by excluding trapped particles from contacting the vaginal 
epithelium4,6 In addition to CVM, our group has also shown that IgG can effectively immobilize individual 
viruses in human lung airway mucus (AM)16,58, as well as highly motile pathogens in mouse 
gastrointestinal mucus (mGIM, unpublished). Our results implicate IgG-mucin crosslinking to be a 
broadly conserved Fc effector function of IgG at mucosal surfaces, reducing the fraction of both bacterial 
and viral pathogens that can penetrate mucus membranes.  
Three distinctive features of antibodies are known to affect their function: (i) the Fc heavy chain 
subclass, (i) Fc-domain glycosylation, and (iii) hinge-region flexibility.  Various Ab isotypes (IgG, IgA) and 
subclasses (IgG1-IgG4, IgA1-IgA2) are structurally heterogenous, differing in hinge length, flexibility, and 
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the angle of the fragment antibody-binding (Fab) arms.119,153,154 Subclasses of the same IgG can elicit 
different target binding affinities due to slight sequence variations in constant heavy chain domains, 
which differentially influence the structure of antigen-binding domains or the overall flexibility of the Ab 
structure.117,165 The effector function of individual IgG subclasses can be further impacted by the N-
glycans on the Fc domain.157,166 Glycosylation of IgA is even more complex, with both O- and N-linked 
glycans on the Fc and Fab regions.159,167  
Although ~10-fold more IgG is found in CVM than IgA37, the predominant Ab isotype associated 
with mucosal protection is secretory IgA (sIgA).37,38,124 Thus, investigating how the potency of Ab-
mediated trapping of viruses in CVM varies between IgA and different subclasses of IgG may help to 
elucidate the most suitable Ab for reinforcing the vaginal mucosa against sexually transmitted 
infections. To do so, we recombinantly expressed six mAbs (IgG1-IgG4, IgA1-IgA2) with identical Fab 
amino acid sequences and comparable affinity to the gD glycoprotein epitope on the HSV-1 virus, and 
used high resolution multiple particle tracking to quantify the diffusion rates of hundreds of individual 
fluorescent HSV-1 virions in fresh, undiluted CVM secretions from reproductive-aged women.  
 
4.2 Results  
4.2.1 Binding affinity and glycosylation profiles for different anti-HSV-1 mAbs 
 
Due to high sequence homology (85%) in the gD epitope between HSV-1 and HSV-1 serotypes, 
the mAb described here (commonly designated as HSV8), binds both HSV-1 and HSV-2, and is currently 
in clinical trial for vaginal Herpes prevention (NCT02579083)2.  Here, we expressed different IgG 
subclasses as well as IgA isotype variants of the same mAb. We confirmed that the molecular weight of 
different mAbs are in good agreement with their theoretical size by SDS-PAGE (Figure 1B), and further 
validated their size and purity using fast protein liquid chromatography (FPLC, Not shown). All six mAb 
were glycosylated as evident by Western blot with Concanavalin A (Figure 1B).  We used mass 
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spectrometry to evaluate the relative composition of the complex N-linked glycan antennary structures 
among all six mAb preparations (Figure 1D). The predominant IgG glycoforms were non-galactosylated, 
with the sum of agalactosylated (G0 and G0F) forms ranging from 44-52% among the four IgG subtypes 
(Figure 1D). Mono- and digalactosylated (G1’ and G1’’) species accounted for ~20% of IgG-associated 
glycoforms. In contrast to IgG, IgA N-glycans are exposed on the protein surface, allowing for more 
extensive glycan processing.159  Consequently, more than 40% of the N-linked glycan structures of both 
IgA1 and IgA2 diverged from the glycan structures that typically account for the majority of Fc-glycoforms 
in IgG.157,168 A large proportion of IgA-associated glycans were mannose-dominant structures  (~27%) 
compared to ~4-18% of IgG-associated glycoforms (Figure 1D), in good agreement with the literature. 
158,159,169 Finally,  using a whole-virus based ELISA and nonlinear curve analysis to measure Ab 
dissociation constants (Kd), we found that all IgG and IgA mAbs bound to HSV-1 with comparable affinity 
(Figure 1C).168  
 
4.2.2 Trapping potencies of different anti-HSV-1 mAbs in CVM  
 
To compare the relative potencies of different mAb subtypes in slowing or immobilizing HSV-1 in 
CVM, we mixed HSV-1 virions with an internal VP22-GFP (green fluorescent protein) tegument protein 
construct, packaged at high copy numbers while maintaining native viral envelope integrity (d ~180nm), 
into undiluted, pH-neutralized CVM treated with different mAbs at a final concentration of 5 µg/mL in 
CVM. We then performed multiple particle tracking to quantify the mobility of hundreds of individual 
viruses in each condition.  
In our model, particles ~200 nm in diameter (HSV d ~180nm) are defined as mobile if they move 
a distance greater than their diameter within 0.2667 s, as described above. The percent of mobile 
viruses was reduced from 76% ± 3% (mean ± SEM) in the control condition to 57% ± 3% and 63% ± 4% 
for IgG1 (p<0.001***) and IgG4 (p<0.05*) conditions, respectively (Figure 2A). There was no statistically 
significant reduction in the percent of mobile viruses in the IgG2 and IgG3 conditions compared to 
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control. While IgA subtypes were more effective at trapping HSV-1 compared to IgG2 – IgG4, trapping 
potency by IgG1 was comparable to both IgA1 and IgA2.  The percent of mobile viruses was 58% ± 4%, and 
56% ± 4% in IgA1 (p<0.01**) and IgA2 (p<0.001***) treated CVM, respectively. 
Virions that possess the greatest diffusivity (i.e. the most mobile) are more likely to diffuse 
across the mucus layer and infect the underlying epithelium before mucus is purged by natural 
clearance mechanisms.  Thus, in addition to the change in effective diffusivities, we also assessed the 
effect of exogenous anti-HSV-1 mAb in reducing the fraction of HSV-1 that could most readily penetrate 
CVM. We quantitatively defined the fast-moving subpopulation as virions that possess sufficient 
mobility to penetrate through a physiologically thick CVM layer (50 µm) in one hour, equating to a 
minimum Deff ≥ 0.347 µm
2/s. 8,28,170  In general, all IgG subclasses effectively reduced the percent of fast-
moving viruses compared to the control condition (Figure 2B). Among the four IgG subclasses, IgG1 was 
the most potent, reducing the percent of fast-moving viruses by ~2-fold, from 34%  ± 3%  to 17% ± 2%,  
(mean ± SEM,  p < 0.0001****).  In comparison, the fast-moving populations were reduced to 19% ± 2% 
and 17% ± 2% for IgA1 and IgA2, respectively (Figure 2B, p < 0.0001****).  While only 33 of 58 CVM 
specimens included in our study had sufficient volumes to allow for direct comparison of all six mAb in 
the same specimen, direct comparison of mAbs within the same samples yielded similar results in Ab-
trapping potency.  
 
4.2.3 Differences in trapping breadth among anti-HSV-1 mAb isotypes   
 
We observed that select mAbs failed to appreciably impact the mobility of HSV-1 in some CVM 
specimens. We quantitatively defined “non-trapping” CVM specimens as those where the fraction of 
mobile viruses was reduced by less than 10% relative to the anti-biotin mAb in the same specimen. 
Interestingly, some CVM specimens trapped HSV-1 when treated with 5 of the 6 anti-HSV-1 mAbs 
tested, while other CVM had appreciable HSV-1 trapping with only 2 of 6 mAbs. IgG1 was clearly superior 
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compared to other IgG subtypes in the “breadth” of enabling muco-trapping, facilitating substantial 
slow-down of HSV-1 in 70% of all CVM specimens tested (Table 1). On the other hand, IgG3 trapped HSV-
1 in just 44% of the CVM specimens. The breadth of trapping by both IgA isotypes was comparable to 
IgG1, substantially slowing HSV-1 in 66% and 73% of IgA1 and IgA2 treated specimens, respectively (Table 
1). In CVM specimens classified as trapping, mAbs of all six types decreased the relative number of 
mobile viruses by 26% - 39% compared to control, and the relative percentage of fast-moving viruses by 
58% - 66%, with all differences statistically significant (Figure 3).  These results indicate that differences 
between Ab isotypes and subclasses in mediating HSV-1 virion retardation in mucus is distinct from HSV-
1 envelope binding, and likely due to underlying differences between different isotypes and components 
of the mucus gel.  
 
4.3 Discussion  
STIs are pandemic worldwide; with the exception of HPV, vaccines against virtually all common 
STIs including Herpes, HIV, Neisseria gonorrhoeae (GC), Chlamydia trachomatis, remain elusive to date. 
Current efforts to elicit durable immunity in the vagina to protect against STIs are likely limited by an 
incomplete understanding of the various mucosal immune defenses in the vagina.5,11  Despite its 
abundance, mucus is typically perceived as strictly a lubricant that limits trauma to the vaginal 
epithelium, and thus rarely serve as a target for immune protection against STIs.  Viruses that transmit 
at mucosal surfaces have evolved to readily penetrate mucus to infect the underlying epithelium; 
indeed, viruses such as HIV, HPV, and HSV can all quickly penetrate human genital mucus. 2,91,170 Thus, 
reinforcing the diffusional barrier properties of mucus with antigen-specific antibodies provides an 
opportunity to limit the flux of HSV-virions arriving at target cells and reduce the incidence of primary 
infection.6,164 Selection of the most potent Ab isotype and subclass that consistently trap or neutralize 
infectious virions in CVM offers the potential to maximize the protection and minimize the costs of 
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localized passive immunization.171  Here, we show here that among common IgG subclasses as well as 
IgA isotypes, HSV-1 virions were most consistently and effectively slowed by HSV-specific IgG1, with 
superior trapping potency to IgG2-IgG4 and comparable to both IgA1 and IgA2. When combined with the 
fact that IgG1 is the most widely used IgG subclass for developing therapeutic antibodies to treat human 
diseases,118,172 and the favored Ab isotype for retention in the acidic environment of the lower FRT,117 
we believe our results further implicate IgG1 to be the most suitable Ab for reinforcing the cervicovaginal 
mucus barrier against STIs.   
Localized passive immunization of the cervicovaginal mucosa offers a number of advantages vs. 
conventional active immunization of the female reproductive tract (FRT).11,105 First, passive 
immunization directly delivers high affinity and broadly neutralizing antibodies that are otherwise 
difficult to induce by active immunization. Second, unlike active immunization that frequently lead to 
substantial variations in Ab titers between different individuals, passive immunization ensures uniform 
protective concentrations across subjects.  Third, due to substantial difference between the volume of 
blood (~5L) and vaginal secretions (~1-2mL), much lower Ab doses are needed to achieve protective 
concentrations locally in the vagina when delivered topically, in contrast to systemic 
administration.105,109,173  Finally, when combined with suitable delivery mechanisms, it is possible to 
sustain protective concentrations of antibodies over time.  Due in part to these advantages, passive 
immunization has been tested against vaginal challenge with HSV or HIV in mice, humans, and non-
human primates (NHP), which highlight the feasibility of using IgG.19,117,174–176 For instance, Zeitlin et.al. 
found no appreciable difference between topically administered anti-HSV-1 monoclonal IgG and its IgA 
variant against the same epitope in preventing transmission of HSV-1 infection in mice.6,175,177 Similarly, 
Parr et.al. identified IgG as the primary protective Ab isotype in mouse vaginal secretions after 
immunization with attenuated HSV-2, and concluded that sIgA contributed relatively little to vaginal 
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immune protection.178  Recent studies have shown that intravaginal ring slowly releasing VRC01 (a mAb 
against HIV) can sustain protective levels in the vagina of rhesus macaques for at least 21 days.179 
The vaccine regimen in the RV144 trial was 31.2% efficacious against HIV infection after 42 
months, underscoring the potential for developing an effective vaccine against HIV.180  Recent evidence 
suggests the protection observed is likely mediated by vaginal IgG.  Since vaginal mucus samples were 
not collected in the original RV144 trial, Akapirat et.al. characterized the Ab response in cervicovaginal 
secretions of RV144 vaccine recipients in a follow up study using a vaccine-boost strategy, where HIV-
uninfected RV144 vaccine recipients were randomized to receive two late-boost intramuscular 
injections with RV144 vaccine components, and quantities of anti-HIV IgA and IgG in undiluted CVM 
were determined.174  While geometric mean titers of anti-gp120 IgG were increased 11-28 fold in CVM 
post boost, gp120-specific IgA was not detected in CVM, despite its presence in plasma. The lack of IgA 
to gp120 in CVM was attributed to the inability of the polymeric immunoglobulin receptor (pIgR) to 
transport monomeric IgA from the plasma into the vaginal lumen. This study implies that achieving 
sufficient concentrations of antigen-specific IgA in the FRT by active immunization is likely challenging. In 
a separate study, only 1 out of 36 trial participants immunized intravaginally developed cervicovaginal 
IgA response post-vaccination, whereas specific IgG antibodies were detected.120  The absence of gp120-
specific IgA also implies that protection against HIV transmission observed in the RV144 trial is likely 
mediated by vaginal HIV-specific IgG.174  It is possible that vaccine-induced vaginal IgG in the RV144 trial 
may help contributed to the observed protection by decreasing the flux of viruses arriving at target cells 
in the sub-epithelium; we have observed that mAb against HIV, including VRC01, can consistently 
immobilize HIV-1 in a subset of women (unpublished observations). 
In general, the rate of transmission of common sexually transmitted viral infections is quite low; 
many intercourses are generally required before a successful transmission event for HIV, HSV and 
HPV.181,182  The requirement for many intercourse events before a successful transmission event implies 
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that few, if any, infectious virions actually reach target cells per intercourse. Thus, reducing the fraction 
of virions that reach target cells will likely lead to a proportional reduction in transmission of infection, 
and possibly even block initial infections altogether.  Viruses trapped in mucus will also be eliminated by 
natural mucus clearance mechanisms (i.e. post-coital discharge).  Finally, Ab-mediated trapping of 
pathogens in mucus is only one of several mechanism by which antibodies can protect against STIs. Ab 
effector functions of IgG1 include neutralization, opsonization, and complement activation,
105,117,119,153 
and viruses can be further inactivated by innate protective mechanisms such as defensins or 
spontaneous thermal degradation.4,6,7,16,164  Crosslinking viruses to mucins, and consequently increasing 
the time needed for viruses to penetrate mucus, will likely synergistically enhance protection by both 
adaptive and innate immune mechanisms by maximizing the time for viral inactivation before the virus 
can reach target cells.  Since antibodies are highly selective in their actions, and are poorly absorbed into 
the systemic circulation, they are likely very safe when dosed intravaginally.  These results strongly 
support further evaluation of IgG1 based Ab constructs for a variety of vaginal passive immunization 
applications.  
 
4.4 Methods and Materials  
4.4.1 Ethics Statement  
Written informed consent of participants was obtained after the nature and possible consequences of 
the study were explained. All studies were performed in accordance with a protocol approved by the 
Institutional Review Board of the University of North Carolina at Chapel Hill (IRB 10-1817). 
 
4.4.2 CVM collection and characterization:   
 
CVM was collected and characterized as previously described170. Detailed methods are provided in  




4.4.3 Culture and purification of fluorescent HSV-1  
The HSV-1 mutant 166v encoding a VP22-GFP tegument protein packaged into HSV-1 
at high copy numbers, was kindly provided by Richard Courtney and used in all microscopy and ELISA 
studies. The addition of GFP to the VP22 protein has no deleterious effects on viral replication, and the 
fluorescence of 166v was consistently more intense than that of HSV-1 mutants encoding other GFP 
fusion proteins183. Virus was expanded at a multiplicity of infection of three on confluent monolayers of 
HaCat cells (Addex Biotech, San Diego, CA) maintained in Dulbecco’s modified Eagle’s medium (Life 
Technologies, Grand Island, NY) supplemented with 5% fetal bovine serum, 1X L-glutamine, and 1X 
Penicillin/Streptomycin. Culture medium was collected 16–18 h post infection and centrifuged at 1,000 x 
g for 5 min to remove cell debris. The resulting supernatant was split into 30-mL aliquots and 
precipitated overnight with a PEG/salt solution. Briefly, 10 ml of 1.55 M NaCl was added to 30 mL of 
crude virus supernatant, followed by 10 mL of 40% PEG 8000 (Sigma, St. Louis, MO). After overnight 
incubation at 4°C, the virus/PEG solution was centrifuged at 2,555 x g at 4°C for 1 h. The virus pellet was 
resuspended in 1X PBS (phosphate-buffered saline) and centrifuged through a continuous 20–50% (w/w) 
sucrose in PBS gradient for 1 h at 74,119 x g. The resulting virus band was further diluted 1:5 in PBS, 
layered over 30% (w/w) sucrose in PBS, and centrifuged for 1.5 h at 83,472 x g to pellet. Purified virus 
pellet was resuspended in PBS and stored as single-use aliquots at 80°C. In this study, we used HSV-1 as 
a model pathogen, as opposed to HSV-2 which is typically believed to be the causative agent of genital 
herpes. However, HSV-1 causes vaginal Herpes with comparable frequency.108,162 
 
4.4.4 Cloning of monoclonal anti-HSV-1 gD antibody isotypes  
 
Variable regions derived from the HSV8 antibody184,185, a neutralizing Ab specific for HSV glycoprotein D 
(gD) first described by Burioni et.al. were cloned into pFUSE vectors (Invivogen, San Diego, CA) with 
constant human heavy chain (IgG1-IgG4, IgA1-IgA2) or light chain backbones using standard cloning 
methods184. Endotoxin free DNA was extracted from transformed bacteria using a Nucleobond xtra Midi 
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Plus EF kit according to manufacturer’s protocol  (Macherey-Nagel, #740422). The same HSV8-specific, 
kappa-light chain expressing plasmid was used for all isotypes (Invivogen #pfuse2ss-hclk), while heavy 
chain plasmids were specific for each isotype.  
 
4.4.5 Cell culture and transient expression of monoclonal HSV8-293 antibody isotypes:  Expi293F™ cells 
were obtained from Invitrogen (Carlsbad, CA) and cultured according to manufacturer’s instructions.  
Twenty-four hours prior to transfection, cultures with over 95% viability were seeded at a density of 1.5 
× 106 cells/mL. Cells were counted on the day of transfection and adjusted to a density of 3.0 X 106 
cells/mL. Heavy and light chain plasmids were co-transfected to produce full length antibodies. For each 
mL of transfection volume, 1 μg DNA of high quality plasmid-DNA were added to Optimem at a 2:3 ratio 
of heavy to light chain. DNA and 293Fectin were complexed for 20-30 minutes before dropwise addition 
to cells. The transfection proceeded for 3-5 days at 125 rpm, 8% CO2 and 37°C. Transfection Enhancer 
was added to cells 16-18 hours post-transfection according to manufacturer’s protocol 
(ThermoScientific,  #A14524). Cells were monitored for viability and glucose levels over the course of 
transfection. When cell viability dropped below 60%, supernatant was collected by spinning down cells 
for 10 min at 1000 rpm and filter sterilized using a 0.22 μM filter. Total IgG or IgA was purified from 
supernatant using Pierce Protein A/G agarose according to manufacturer’s instructions adapted to a 
batch capture method (ThermoScientific, #20422). Elution fractions were buffer exchanged into 
Dulbecco’ s Phosphate Buffer Saline. Ab concentration was quantified by nanodrop and verified with 
total IgA or IgG ELISA. Binding of HSV8-293 Abs was verified by an HSV-specific ELISA using whole virus 
and polyclonal anti-HSV-IgG as a positive control.  
 
4.4.6 Preparation and characterization of polyclonal anti-HSV-1 IgG  
 
Polyclonal Anti-HSV-1 IgG was purified from intravenous immunoglobulin (IVIg, Privigen®; ≥ 98% IgG; CSL 
Behring, King of Prussia, PA) by affinity column purification as previously described.  
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4.4.7 Enzymatic removal of Fc N-linked glycans using PNGase F. N-glycans were removed from 
antibodies following the manufacturer's standard protocol for Peptide N-Glycosidase F (PNGase F, Sigma 
P7367). Briefly, Ab solutions for deglycosylation were prepared by buffer exchanging 200 µg of mAb into 
20 mM ammonium carbonate. Denaturing solution was added and the sample was heated to 100 °C for 
10 minutes. After cooling, 20 µL of Triton X-100 (Sigma 93443) was added, and the sample was gently 
mixed. Prepared PNGase F was added to the reaction mixture and incubated at 37 °C for 1-3 hrs. The 
reaction was stopped by heating the sample to 100 °C for 5 minutes, then placed on ice to stop further 
enzymatic digestion. Sample was then buffer exchanged into sterile PBS using a 50K MWCO filter  
(Millipore-Sigma UFC505008). Flow through was analyzed by SDS-PAGE. Ab concentration was measured 
using a NanoDrop One instrument (ThermoScientific). Samples were stored at 4 °C until use.  
 
4.4.8 SDS-PAGE and Western Lectin Blot to validate Fc N-glycan removal. Protein samples (5 µg) were 
prepared for SDS-PAGE by diluting in ultrapure water and mixing with 4X protein sample buffer 
(Invitrogen #NP0007) and 1 uL dithithreitol (Sigma #43816) to a final volume of 15 µL. Samples were 
heated at 70 °C for ten minutes and resolved by SDS-PAGE. Two gels were run simultaneously for silver 
stain (Pierce Silverstain kit, ThermoScientific 24612) and lectin blotting.  Proteins were transferred from 
the gel to a nitrocellulose membrane using a Novex® Semi-Dry blotting apparatus at 20 V for 45 minutes 
(ThermoScientific SD1000). The membrane was rinsed several times with 0.1% PBST and blocked with 1X 
Carbo-Free™ Blocking Solution (Vector Labs SP-5040) and for 1hr at RT. Biotinylated, mannose-specific 
Concanavalin A lectin (ConA) was added to the membrane at a concentration of 2 µg/mL in PBS and 
incubated overnight at 4 °C with rocking (Vector Labs B-1005). After washing, anti-biotin HRP (Vector 
Labs SP3010) was added to the membrane at a 1:10,000 dilution in 0.1% PBST for 1 hr at RT. Bio-Rad ECL 
reagent (Bio-Rad 107060) was used to develop the blot according to manufacturer’s instructions.  The 
gel was silver stained according to manufacturer’s instructions (Pierce Silverstain kit, ThermoScientific 
24612) and imaged using a Biorad gel imaging system.  
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4.4.9 Glycosylation analysis of monoclonal anti-HSV-1 antibody isotypes  
N-Glycans were analyzed with a LabChip GXII Touch HT (Perkin Elmer) device according to a protocol 
developed by the vendor to determine the relative distribution of N-linked complex biantennary 
structures with a core fucose, typical of monoclonal antibodies. Briefly, glycans were released from the 
mAb sample with treatment of PNGase F as described. Glycan samples were placed into a 96 well 
microtiter plate and fluorescently labelled. Labelled samples were taken up into a microfluidic chip and 
separated into a 20 mm polymer filled channel.   Individual sample peaks were compared with a battery 
of glycan standards to allow qualitative and quantitative determination of glycan identity. 
 
4.4.10 HSV-specific binding ELISA and calculation of mAb affinity to HSV-1  
Whole-virus ELISA was used to verify binding of HSV-1 specific mAbs to virus. Briefly, high-affinity 96-
well, half-area plates (ThermoScientific, Rockford, IL) were coated with 25 μL per well of affinity-purified 
intact HSV-1 at 20 μg/mL (measured using BCA assay) and incubated overnight at 4°C. The following day, 
virus was UV-inactivated in a sterile culture hood for 1 hr at room temperature. Plates were washed five 
times with 0.05% Tween in PBS (PBS-T), blocked with 5% milk for a minimum of 1 hr followed by PBS-T 
washes, then incubated for at least 1 hr with serial dilutions of individual mAbs. Following PBS-T washes, 
virion-bound Ab was detected using  anti-human kappa light chain-HRP conjugate (Sigma, A7164) and 1-
Step Ultra TMB substrate (ThermoScientific, Rockford, IL). TMB conversion was terminated with 2 N 
sulfuric acid, and absorbance was measured at 450 nm and 570 nm using a SpectraMax M2 plate reader 
(Molecular Devices). Kd values of mAb binding to HSV were calculated using nonlinear curve analysis in 
GraphPad Prism by plotting nanomolar Ab concentrations versus absorbance (n=3 plates per Ab).  
 
4.4.11 Multiple-particle tracking of HSV-1 in CVM 
 
To mimic neutralization of CVM by alkaline seminal fluid, we titrated CVM to pH 6.8–7.2 using 
 
70 
small volumes (3% v/v) of 3 N NaOH and confirmed pH using a pH microelectrode (Microelectrodes, 
Bedford, NH) calibrated with pH 4, 7, and 10 buffers. Samples were either treated or untreated by the 
addition of known amounts of purified anti-HSV-1 mAbs or control (anti-biotin) IgG pre-mixed with 
fluorescent virions (approximately 108–109 particles/mL) and incubated at 37°C for 15-30 minutes prior 
to adding to 20 µL CVM in a custom-made glass chamber. Once mixed, Abs, virus, and CVM were 
incubated at 37°C for and additional 15-30 minutes prior to microscopy. Control beads consisted of red 
or green fluorescent 200nm carboxyl-modified PS particles (Molecular Probes, Eugene, OR), either 
uncoated (PS; muco-adhesive) or covalently conjugated with a low molecular weight (2 kDa), amine-
functionalized PEG (Rapp Polymere, Tuebingen, Germany) to produce coated particles (PS-PEG; muco-
inert) as previously described28. Translational motions of the particles were recorded using an electron 
multiplying charge-coupled-device (EMCCD) camera (Evolve 512; Photometrics, Tucson, AZ) mounted on 
an inverted epifluorescence microscope (AxioObserver D1; Zeiss, Thornwood, NY) equipped with an 
Alpha Plan-Apo 100/1.46 numerical-aperture (NA) objective, an environmental (temperature and CO2)-
control chamber, and light-emitting-diode (LED) light source (Lumencor Light Engine 
DAPI/GFP/543/623/690). Videos (512X512 pixels, 16-bit image depth) were captured with MetaMorph 
imaging software (Molecular Devices, Sunnyvale, CA) at a temporal resolution of 66.7 ms and spatial 
resolution of 10 nm (nominal pixel resolution, 0.156 µm/pixel) for 20 s. The tracking resolution was 
determined by tracking the displacements of particles immobilized with a strong adhesive, following a 
previously described method.186  Particle trajectories (xy locations) were obtained using a recently 
developed tracking software based on convolutional neural networks.187  Trajectories were analyzed 
using “frame-by-frame” weighting in which mean squared displacements (MSD) and effective 
diffusivities (Deff) are first calculated for individual particle traces.
188  Averages and distributions are then 
calculated at each frame based on only the particles present in that frame before averaging across all 
frames in the movie. This approach minimizes bias toward faster-moving particle subpopulations. 
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Trajectories of at least 40 particles per frame on average were analyzed for each experiment, which 
typically corresponds to greater than 100 individual particle traces throughout the video and is 
consistent with sampling in our previous work.6,97  Trapped particles were defined by a Deff value of 
<.0316 µm2/s at a value of 0.2667 s (time scale corresponding to a minimum trajectory length of 5 
frames); for particles 200 nm in diameter and larger, this cutoff translates to particles moving a distance 
much less than their diameter within 0.2667 s.  
 
4.4.12 Statistical analysis 
Statistical comparisons were performed using a two-tailed Student’s t-test (paired) or ANOVA with 
multiple comparisons between matched samples (Tukey’s multiple comparison test) using GraphPad 
Prism version 7.0 (GraphPad Software, La Jolla, CA). Alpha was 0.05. Results are reported as mean ± 







Figure 4.1: Anti-HSV-1 antibodies have similar HSV-1 binding affinity and glycosylation. 
(A) Schematic of different monoclonal antibody subtype structures indicating how heavy chains are 
linked, the length of the hinge, the number of disulfide bridges connecting the two heavy chains, and O 
and N-linked glycosylation sites. (B) SDS-PAGE gel and Concanavalin A Western lectin blot showing size 
and deglycosylation of anti-HSV-1 mAbs. (C) Kd binding constants of anti-HSV-1 mAbs to HSV-1 
measured by whole virus ELISA. (D) Relative glycan composition of IgG1-IgG4 and IgA1-IgA2 monoclonal 













Figure 4.2: HSV-1 mobility in CVM with exogenously added monoclonal anti-HSV-1-gD or anti-biotin 
IgG control. (A) Percent of mobile viruses and (B) Percent of fast-moving viruses in CVM treated with 
either 5 µg/mL of various anti-HSV-1-gD mAb  (IgG1-IgG4, IgA1-IgA2) or 5 µg/mL IgG1 anti-biotin. Data 
presented as mean ± SEM, (N= 41-50 per group). One-Way ANOVA (p < 0.05*, p < 0.01**, p<0.001***, p 































Table 4.1: Frequency of individual anti-HSV-1 gD monoclonal Abs which facilitated trapping of HSV-1 
in different CVM specimens.  Trapping samples were defined as those in which anti-HSV-1 mAb reduced 
the percent of mobile viruses by at 10% or greater relative to the anti-biotin control condition in the 






















Figure 4.3: Trapping potency of individual anti-HSV-1 mAbs in “trapping” versus “non-trapping” CVM. 
Percent of mobile viruses in CVM samples classified as (A) trappers or (B) non-trappers in the presence 
of various anti-HSV-1-gD mAbs at 5 µg/mL. Trapping samples were defined as those in which anti-HSV-1 
mAb reduced the percent of mobile viruses by at 10% or greater relative to the anti-biotin control 















































Antibody Isotype IUD Combination Pill None ≤  4.0 ≥ 4.01 ≤  1.49 ≥ 1.5 ≤  4.99 ≥ 5 (%) 
IgG1 85 70 75 76 50 70 70 71 70 70 
IgG2 36 67 60 58 45 72 41 44 63 55 
IgG3 25 53 60 55 17 48 43 41 48 44 
IgG4 50 65 50 62 36 45 61 27 68 54 
IgA1 67 64 80 69 55 75 58 63 68 66 
IgA2 89 74 75 74 70 78 70 64 79 73 
           
 
Table 4.2 (Supp.Table 1):  Percent of samples trapped by individual anti-HSV-1 gD monoclonal Ab isotypes classified by birth control status, cycle 




Sample native pH 
D-Lactic Acid  
(mg/mL CVM) 
L-Lactic Acid  
(mg/mL CVM) 
Total LA D:L Ratio 
1 3.0 4.5 2.7 7.2 1.7 
2 3.1 4.5 0.9 5.5 4.9 
3 3.1 6.4 1.6 8.0 4.1 
4 3.3 2.3 5.6 7.9 0.4 
5 3.3 1.6 1.3 2.9 1.3 
6 3.3 1.4 4.0 5.5 0.4 
7 3.3 7.6 2.4 10.0 3.2 
8 3.3 0.0 3.3 3.3 0.0 
9 3.4 7.1 4.2 11.3 1.7 
10 3.4 6.7 2.4 9.1 2.8 
11 3.4 1.3 3.1 4.4 0.4 
12 3.4 6.7 2.1 8.8 3.2 
13 3.4 4.7 0.8 5.5 5.8 
14 3.4 4.6 1.6 6.3 2.8 
15 3.4 2.4 1.6 4.1 1.5 
16 3.5 8.1 2.3 10.4 3.6 
17 3.5 1.6 1.5 3.1 1.1 
18 3.5 8.1 3.3 11.3 2.5 
19 3.5 1.6 1.7 3.2 0.9 
20 3.5 7.0 2.2 9.2 3.2 
21 3.5 5.1 2.7 7.8 1.9 
22 3.5 0.0 1.9 1.9 0.0 
23 3.5 0.0 3.5 3.5 0.0 
24 3.5 0.0 3.4 3.4 0.0 
25 3.6 8.6 5.1 13.7 1.7 
26 3.6 8.6 3.3 11.8 2.6 
27 3.6 5.0 2.8 7.8 1.8 
28 3.6 7.5 3.3 10.8 2.3 
29 3.6 3.7 1.3 4.9 2.9 
30 3.6 6.2 3.9 10.1 1.6 
31 3.7 9.4 2.9 12.3 3.2 
32 3.7 2.2 1.6 3.8 1.4 
33 3.7 0.7 8.9 9.6 0.1 
34 3.7 3.7 1.1 4.8 3.5 
35 3.7 5.6 2.8 8.4 2.0 
36 3.8 1.4 1.1 2.4 1.3 
37 3.8 7.9 2.7 10.6 2.9 
38 3.8 3.3 0.6 3.8 5.9 
39 3.8 6.8 1.8 8.5 3.9 
40 3.8 5.4 3.9 9.4 1.4 
41 3.8 3.8 2.5 6.3 1.5 
42 3.9 6.4 2.0 8.3 3.2 
43 4.0 0.0 4.2 4.2 0.0 
44 4.0 5.8 3.6 9.3 1.6 
45 4.0 0.3 7.9 8.2 0.0 
46 4.1 1.0 4.7 5.6 0.2 
47 4.1 2.6 0.7 3.3 3.7 
48 4.1 6.3 2.8 9.1 2.3 
49 4.2 0.0 3.5 3.5 0.0 
50 4.2 4.8 1.7 6.4 2.9 
51 4.3 3.2 3.5 6.8 0.9 
52 4.3 1.2 2.8 4.0 0.4 
53 4.7 1.1 2.6 3.7 0.4 
54 4.7 0.0 0.8 0.8 0.0 
 
Table 4.3 (Supp.Table 2): Native pH, D, L, and total lactic acid content (mg/mL CVM), and ratio of D:L 
Lactic Acid in CVM samples tested in this study. 
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Enteric pathogens, including viruses and intracellular obligate bacteria, must first penetrate the 
gastrointestinal mucus (GIM) layer to reach and infect the host epithelium.24,125,150  In the case of 
Salmonella,  the bacteria must also  come into direct contact with host cells to establish initial 
attachment and inject virulence effectors via the type III secretion system (T3SS).61  These longstanding 
observations suggest that limiting mucus penetration should provide an effective way to prevent and/or 
treat infections.  The dense network of mucin fibers is capable of sterically obstructing diffusion of 
particles that are too large to fit through the pores in mucus. Mucous can also form direct adhesive 
bonds with foreign particles to impede the movement of particles that are smaller than the mucous 
pore size.1,57 Bacteria have evolved a variety of mechanisms to avoid becoming immobilized in mucus,27 
such as active flagellar motility66 or secretion of enzymes that degrade mucins.57,121   
Antibodies are abundant in mucus, including IgG. 36–38,115 Interestingly, the diffusion of IgG and 
IgA antibodies in mucus is only slowed ~10-20% compared to in buffer; this implies that the vast 
majority of IgG and IgA molecules are not interacting with mucins at any moment in time, and that any 
bond with mucins is exceptionally short-lived.8,14,15 Despite this seemingly negligible affinity, we recently 
showed that IgG can effectively immobilize individual viruses in both fresh, undiluted human lung airway
                                                        
2 This chapter is based on an article submitted to Mucosal Immunology. Holly A. Schroeder, Jay Newby, 
Alison Schaefer, Babu Subramani, Alan Tubbs, M. Gregory Forest, Ed Miao, Samuel K. Lai.( 2018). LPS-
binding IgG arrests actively motile Salmonella Typhimurium in gastrointestinal mucus. 
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mucus (AM) isolated from extubated endotracheal tubes16 and in human CVM recovered from an 
inserted menstrual cup. 6,164 IgG-mediated virion immobilization is attributed to the presence of multiple 
low-affinity bonds between the array of bound IgG to individual virions and mucins,6 specifically 
mediated by N-glycans on the Fc domain of IgG.  Trapping in mucus directly precludes access to 
underlying cells,4 facilitates rapid elimination through natural mucus clearance mechanisms,16  and 
blocks vaginal Herpesvirus transmission in vivo.6 These findings underscore the ability for antibodies, 
either secreted by the immune system or topically delivered to mucosal surfaces, to reinforce the 
mucosal barrier against foreign pathogens. 
Despite the strong evidence that IgG can trap viruses in AM and CVM secretions, it remains 
unclear if topically delivered IgG could reinforce the barrier properties of GIM, particularly against highly 
motile bacterial pathogens.  First, AM and CVM are composed primarily of MUC5B mucins (with modest 
levels of MUC5AC), whereas mucins produced locally in the GI tract are comprised primarily of 
MUC2.24,121  Despite their biochemical similarity, members of the mucin family can vary considerably in 
length and sequence of tandem repeats, size, and glycosylation.31,50,123 Thus, it remains unproven 
whether IgG-Fc would possess the appropriate affinity to MUC2 and other mucins in GIM to enable 
crosslinking of pathogens to the mucin mesh.  Second, although IgG is by far the dominant Ab, 37,115 and 
substantial quantities of IgG are present in AM,36 the predominant Ab in GIM is secretory IgA (sIgA).38,124 
This may be construed to implicate sIgA, and not IgG, as the only suitable immunoglobulin in the GI 
tract.  Third, unlike viruses that permeate mucus by undergoing Brownian motion in low viscosity 
interstitial fluids between the mucin mesh, actively motile bacteria can quickly swim through mucus.  In 
turn, there is a much shorter time window for adequate number of Ab molecules to accumulate on the 
surface of the bacteria to immobilize the bacteria in the mucus gel, before the bacteria actually reaches 
the underlying epithelium.  Further, there must be a much greater number of bound IgG on the bacterial 
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surface to generate the additional avidity to counteract the forces generated by active flagella beating, 
compared to bound IgG on viruses whose motion is driven by thermal excitation.  
To investigate whether IgG could reinforce GIM against active bacteria, we performed high 
resolution video microscopy to capture how lipopolysaccharide (LPS)-binding IgG could alter the motion 
of fluorescent Salmonella enterica serovar Typhimurium (S. Typhimurium) in fresh GIM isolated from the 
mouse intestinal tract.  Surprisingly, we found that IgG was able to arrest highly motile S. Typhimurium  
in GIM and markedly reduce the flux of Salmonella that could penetrate through mucus.  
 
5.2 Results  
5.2.1 Anti-LPS IgG alters the distribution of Salmonella motility in mouse GIM 
We collected fresh undiluted GIM from Rag1–/– mice, which lack mature B-and T lymphocytes, 
thus eliminating endogenous antibodies that might cross react with S. Typhimurium surface Ags. 189  
Then, using high-resolution multiple particle tracking, we quantified the motion of fluorescent S. 
Typhimurium in GIM treated with either anti-LPS or anti-biotin IgG (control mAb).  In untreated GIM (no 
mAb) as well as treated with control mAb to a final concentration of 5 µg/mL, determined to be 
physiologically relevant and sub-agglutinating concentrations in our experimental setting 
(Supplementary Figure 1), there was substantial heterogeneity in the S. Typhimurium motion: some 
appeared to not move at all, some appeared to undergo undirected Brownian-like motion, and a 
substantial fraction exhibited large, directed displacements (Figure 1A, Supplementary Video 1), in good 
agreement with previous reports.66–68 In contrast, in aliquots of GIM from the same mouse but treated 
with 5 µg/mL anti-LPS IgG, the collective motion of the S. Typhimurium  appeared visually distinct 
(Supplementary Video 2).  Specifically, there were substantially more bacterial traces reflecting hindered 
motion, and a reduced number of traces with long, directed displacements. Importantly, non-specific 
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anti-biotin IgG (Control mAb) did not alter Salmonella mobility in mGIM compared to Salmonella 
mobility in the absence of exogenous mAb (no mAb, Supplementary Figure 2).  
Bacteria are known to undergo “run-and-tumble” motion: a bacteria can exhibit long range 
active motility in one instant, and restricted tumbling motion the next instant.68,152 To robustly analyze 
the impact of S. Typhimurium-binding IgG on S. Typhimurium motion in GIM, we developed a hidden 
Markov Model framework190–193 capable of categorizing each time increment within a bacterial trace 
into one of three groups: ”immobilized,” “hindered/diffusive” or “swimming,” illustrated by 
representative traces in Figure 1. Individual trace increments, were classified using a three-state Markov 
process to model the state-dependent motion of bacteria. In the swim-state, bacterial motion is 
directed in a random direction. In the hindered state, motion is undirected and diffusive. In the final 
immobilized-state, motion is also undirected but substantially hindered. Using this framework, we were 
able to quantify how anti-LPS IgG impacted the total number of increments spent by an  individual S. 
Typhimurium bacteria in a particular  motion-state. In bacterial traces with directed motion, the 
presence of IgG anti-LPS appeared to markedly reduce the distance traveled by individual bacteria 
compared to control mAb (Figure 1B).  In matched mGIM samples, we observed a modest but 
statistically significant increase in the total number of trace increments defined as immobilized in the 
presence of anti-LPS IgG compared to control mAb.  Specifically, of all trace increments measured, the 
percentage of increments categorized as “immobilized” increased from 35 ± 12% in the anti-biotin 
control to 41 ± 14% with anti-LPS IgG (Figure 1B, p < 0.05*).  Similarly, the percent of increments 
classified as “hindered/diffusive” was increased from 48 ± 7% in the control mAb condition to 53 ± 11% 
in the presence of anti-LPS IgG. The greatest change was observed in the total number of trace 
increments classified as swimming between the two mAb conditions:  anti-LPS IgG reduced the 
percentage of swimming  increments by 73%, from 16 ± 10% (control mAb) to 6 ± 6% (Figure 1B, p < 
0.0001****).   
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Taking advantage of the Hidden-Markov Model framework’s capacity to classify individual trace 
increments into one of the three motion states on an increment-by-increment basis, we used Maximum 
Likelihood estimation190–193 to infer the average transition rates into or out of the different motion states 
(e.g. from immobilized to hindered, or swim to hindered, etc.), which may offer insight into the mucus-
penetration capacity of individual bacteria over longer periods of time. We found that anti-LPS IgG 
markedly changed the bacteria’s transition rates between directed (i.e. swimming) and undirected 
(hindered or immobilized) motion (Figure 1C-1D), but not the transition between the two undirected 
motion states (i.e. immobilized vs. hindered) (Supplementary Figure 3).  Specifically, the average rate of 
S. Typhimurium  transitioning from the hindered to swim state decreased from 0.41 ± 0.19 transitions 
per second in control IgG to 0.25 ± 0.12 per second with anti-LPS IgG, indicating that anti-LPS IgG made 
it less likely for S. Typhimurium  to initiate undergoing directed swimming motion with large 
displacements (Figure 1C, p < 0.001***).  Similarly, the average rate of S. Typhimurium  transitioning 
from the swim to hindered motion-state was markedly increased from 1.37 ± 0.54 per second in control 
IgG to 2.74 ± 0.67 per second with anti-LPS IgG, indicating that the presence of anti-LPS IgG made it 
twice as likely for an actively swimming S. Typhimurium  to stop swimming and transition to the 
hindered motion-state (Figure 1D, p < 0.0001****).  These observations imply that bacterial tethering to 
mucus by pathogen-bound antibodies may reduce the overall distance traveled of individual bacteria (by 
reducing the frequency of large, directed displacements), potentially limiting bacterial invasiveness.  
 
5.2.2 IgG anti-LPS decreases the amount of time Salmonella spend swimming with directed motion 
Several studies have corroborated that bacteria moving in a tumbling or ‘undirected’ fashion are 
less invasive than swimming bacteria moving with ‘directed’ motion.67,68,152 Therefore, we sought to 
explore the effect of anti-LPS IgG on the most mobile S. Typhimurium populations in GIM. We stratified 
the most actively swimming population by sorting for Salmonella that remained swimming for the 
longest duration, (i.e. bacterial traces that underwent swimming motion of at least five consecutive 
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increments, or  swimming for at least ~330 ms at a time). The percentage of traces with extended-
swimming bacteria decreased from 37 ± 16% in the control mAb condition to 16 ± 11% in the presence 
of IgG anti-LPS (Figure 2A, p < 0.0001****). Next, for these bacterial traces with sustained swimming 
motion, we calculated the percent of the time spent in the swimming state based on the total number 
of increments in each trace that were classified as swimming over the entire length of the trace (Figure 
2B). In GIM treated with anti-LPS IgG, bacteria spent a shorter fraction of time (78 ± 7%) in the swim-
state overall, compared to in GIM treated with control mAb (88 ± 5% )to (Figure 2B, p < 0.001***). The 
average velocity of bacteria while in the swim state (velocity of swim increments) in the presence of IgG 
anti-LPS was 7.1 ± 1.0 µm/sec compared to 9.6 ± 1.7 µm/sec with control mAb (Figure 2C, p < 
0.0001****).  
 
5.2.3 IgG-mediated trapping of Salmonella in mGIM is dependent upon the Fc-glycan 
We previously showed that N-glycans on the asparagine-297 residue of the Fc-region of IgG 
heavy chain are critical to IgG-mediated trapping of Herpes Simplex Viruses in CVM.6 Therefore, we 
sought to explore whether IgG-mediated tethering of individual bacteria to the mucin matrix was 
mediated by the same mechanism. We used PNGase F, an enzyme with cleavage specificity for N-linked 
glycans, to remove the Fc-glycan from the IgG heavy chain, and verified complete deglycosylation of the 
anti-LPS IgG using a concanavalin A-specific western lectin blot (Figure 3A).  Deglycosylation of the anti-
LPS IgG did not appear to appreciably alter its binding affinity to the S. Typhimurium  (Figure 3B).  
Deglycosylation appeared to nearly completely eliminate the ability for anti-LPS IgG to 
immobilize S. Typhimurium, with the percent of swimming increments increasing nearly three-fold (18 ± 
10%) compared to in the native IgG anti-LPS condition (6 ± 6%)  (Figure 3C, p < 0.001***), but  no 
statistically significant difference between deglycosylated anti-LPS IgG and control mAb. In addition, the 
rate of S. Typhimurium transition from the hindered state to the swim state was much greater (0.42 ± 
0.24/s vs. 0.26 ± 0.13/s), and the transition rate from swim to hindered state lower  (1.3 ± 0.39/s vs. 2.7 
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± 0.56/s) for native IgG anti-LPS compared to its deglycosylated counterpart (Supplementary Figure 3C , 
p < 0.01**, p < 0.0001****). Ultimately, the lack of changes in these transition rates  resulted in an 
overall greater amount of time spent swimming  by S. Typhimurium in the deglycosylated IgG anti-LPS 
and control mAb conditions compared to in the native IgG anti-LPS condition (Figure 3E, p < 0.001***). 
Finally,  deglycosylated anti-LPS IgG failed to reduce the fraction of bacteria undergoing extended 
swimming motion (Figure 3D, p < 0.001***), as well as the velocity of those bacteria while in the 
swimming state compared to native IgG anti-LPS (9.7 ± 2.0 µm/sec vs. 7.1 ± 0.7 µm/sec, Figure 3F, p < 
0.001***). All observations in the deglycosylated anti-LPS IgG condition were indistinguishable from 
control IgG, strongly implicating the involvement of Fc N-glycans in IgG-mucin crosslinking.  
 
5.2.4 IgG anti-LPS limits Salmonella penetration across mGIM in an Fc N-glycan dependent manner 
The protective properties of mucus are naturally dependent on the thickness of the barrier, and 
minimizing the fraction of pathogens that penetrate this layer may in turn reduce the probability of 
infection.194  We first used in silico modeling to evaluate the potential effectiveness of IgG-mediated 
trapping of S. Typhimurium  in mGIM, based on the experimental measurements above. Using 
parameters derived from Hidden-Markov simulations (see Table in Methods section), we calculated the 
first-passage times, (i.e. the fraction of Salmonella that would theoretically penetrate a GIM layer of 
physically defined thickness over time187,194 (0 – 1000 µm) under different IgG-treated conditions (Figure 
4). We found that the fraction of S. Typhimurium  that could penetrate the GIM layer over at least the 
first five hours was significantly reduced by IgG1 anti-LPS across all theoretical mucus thicknesses (Figure 
4C), while bacterial penetration by Salmonella in the presence of deglycosylated  anti-LPS IgG (Figure 4B) 
was indistinguishable from control IgG (Figure 4A). For instance, extrapolating from the plotted 
simulations, in a 200 µm thick mucus layer, native IgG anti-LPS reduced the fraction of S. Typhimurium  
permeating GIM within one hour by about two-fold, to ~50% compared to ~90-100% in both the control 
mAb and deglycosylated anti-LPS IgG conditions.  With greater GIM thicknesses, e.g. 500 µm, few if any 
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S. Typhimurium  would be able to permeate GIM containing 5 µg/mL IgG anti-LPS within five hours, 
versus nearly 80% of S. Typhimurium  in GIM containing control mAb or deglycosylated anti-LPS IgG. 
To validate our in silico observations experimentally, we developed a transwell assay using fresh, 
undiluted mGIM with the experimental setup illustrated in (Figure 5A). In good agreement with our 
expectations, native anti-LPS IgG markedly reduced S. Typhimurium translocation across an 
approximately 10 mm thick mucus layer over four hours in a dose-dependent manner (Figure 5C), while 
deglycosylated anti-LPS IgG failed to limit bacterial penetration (Figure 5B). Salmonella growth was not 
impaired in the presence of IgG anti-LPS F(ab) up to 10 µg/mL , implying that IgG binding to S. 
Typhimurium  did not induce bacterial death or inhibit bacterial growth over time (Figure 5D).  
Additionally, when the transwell assay was repeated with increasing concentrations of IgG anti-LPS F(ab) 
(0-10 µg/mL), Salmonella retained its capacity to penetrate mGIM.  Together, these results further 
validate the requirement for both antigen-specificity and interaction of the Fc-region with the mucus gel 
for effective Ab-mediated trapping of pathogens in mucus. 
 
5.3 Discussion  
The human intestinal tract is exposed to an abundance of diverse microorganisms. As the largest 
mucosal surface in the body, the gut mucosal immune system faces a constant battle between 
eliminating potential pathogens and maintaining homeostasis with commensal microbes.70,124  An 
abundance of antibodies (particularly sIgA)- are secreted into GIM to maintain this mutually beneficial 
relationship. Recent work is beginning to shed light on the protective role of sIgA in mucus, including 
immune exclusion based on sIgA-induced agglutination, resulting in bacteria-sIgA complexes that are too 
large to permeate GIM.70 Interestingly, IgA deficiencies occur on the order of 1 in 300 to 1 in 600 
people,167 yet the vast majority of IgA-deficient individuals (~85-90%) remain asymptomatic. This 
suggests that other immunoglobulins, such as IgM or IgG, can likely compensate for part of sIgA function 
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in mucosal protection.195 Additionally, IgG can enter the lumen of the GI tract during infection and have 
a significantly beneficial effect in combatting the infection.196 Here, consistent with that hypothesis, we 
show for the first time that IgG is capable of fortifying the GIM barrier against highly motile bacteria at 
physiologically relevant, sub-agglutinating concentrations of IgG. Specifically, the array of IgG-bound to 
an individual bacteria can crosslink the bacteria to the mucin mesh via N-glycans on IgG-Fc. While the 
affinity of individual IgG molecules with mucins is low, the high valency of anti-LPS antibodies binding to 
many epitopes, combined with the relatively large surface area which these epitopes are displayed 
across the surface of the bacteria, results in a high avidity of the IgG-mucin interaction which can 
accomplish bacterial immobilization (Figure 6).8,14,15  Consequently, this increases the rate of bacteria 
transitioning from swimming to tumbling/diffusive states, decreases the duration of extended swimming 
motion, and reduces their swimming velocity.  
Several studies have shown that disruption of bacterial motility attenuates disease and reduces 
bacterial invasiveness.56,67,68,152 Stecher et.al. determined that S. Typhimurium  with mutations in 
flagellar machinery had reduced fitness, while flagellated sub-populations accumulated at the 
epithelium.67 Similarly, Pontier-Bres et.al. showed that mutant strains of S. Typhimurium exhibiting 
“smooth” swimming patterns were more invasive than mutants with “tumbly” swimming patterns, and 
more effective at entering Peyer’s patches in an intestinal loop model.152 Finally, Le Moal et.al. showed 
that inhibition of S. Typhimurium swimming motility led to delayed entry into human mucus-secreting 
HT29-MTX cells.68  Given the body of literature that describes the impaired invasiveness of slowed or 
immobilized Salmonella, particularly the observation that non-motile mutants of S. Typhimurium are 
30–50 fold less invasive than their parental wild type strains,70,151,197 we speculate that the muco-
trapping effector function of IgG, may protect against bacterial infection in the GI tract by reducing 
bacterial flux across GIM.  
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Flagellar-mediated motility through mucus can be a prerequisite for successful mucosal 
colonization.66 The flagellar motor generally rotates counter-clockwise (CCW), propelling the cell 
forward with directed motion. When flagella switch to a clockwise direction, bacteria may enter a 
transiently tumbling state.56,198  In Salmonella, switching directions by the flagellar motor has been 
associated with shifts in chemotaxis or transmembrane electrochemical proton gradients.198 In a study 
by Xu, et.al. Salmonella treated with a physiological concentration of mannose-binding lectin (MBL) 
exhibited reduced swimming speed and an overall reduction in the motile fraction of bacteria compared 
to untreated cells.56  Using a rotation assay, the authors determined that the flagellar rotation rate was 
significantly reduced as a result of a change in intracellular pH and membrane potential. Importantly, 
mannose-rich LPS is highly expressed by Salmonella. Since the exact epitope of the anti-LPS IgG used 
herein is unknown, it is possible that some of the Ab-induced motility arrest we observed may be 
mediated by a similar mechanism. Nevertheless, the total fraction of Salmonella exhibiting swimming 
motility reported by Xu et.al. was only reduced by 15% in the presence of MBL. In contrast, we observed 
a 73% reduction in the swimming population of Salmonella in the presence of both mucus and anti-LPS 
IgG, suggesting that IgG-mediated tethering to mucins may enhance bacterial motility arrest, 
independent of biochemical interference with flagella.56  
A study by Forbes et.al. determined that monoclonal IgA against Salmonella (Sal4) and 
polyclonal anti-LPS IgG were potent inhibitors of flagellum-based Salmonella motility, independent of 
agglutination. 70 Similarly, Levinson et.al. reported that LPS-specific IgA (2D6) was a potent inhibitor of 
flagellum-based motility of Vibrio cholerae in both semisolid agar and liquid medium. It was determined 
that 2D6 promoted flagellum-flagellum cross-linking, leading to flagellar entanglement and 
consequently, motility arrest.149  In the same study, Levinson et.al. reported that monovalent 2D6 IgG-
Fab fragments inhibited V. cholerae motility by a similar mechanism. These results raise the question of 
whether the increased fraction of Salmonella we observed in the “tumbling/hindered” motion state in 
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the presence of LPS-specific IgG was perhaps a result of Ab-induced flagellar cross-linking. In line with 
these observations, it is possible that Ab-mediated retardation of Salmonella in GIM was partially 
mediated by Ab-interference with bacterial flagellar motion. However, our transwell assay results with 
IgG-LPS Fab fragments suggest that while Fab binding may impair flagellar motion, this alone was 
insufficient to limit bacterial penetration across mucus. Assuming that Fab binding to Salmonella elicited 
comparable motility arrest as binding by whole Ab in our studies, yet did not reduce penetration across 
mucus, inhibition of bacterial penetration was likely mediated IgG-mucin cross-linking, resulting in 
bacterial entrapment.  
Members of the mucin family can vary considerably in length and sequence of tandem repeats, 
size, and glycosylation,31,50 and different mucins are dominant in the GI tract vs. the lung airways or the 
female reproductive tract.36–38,124 Despite these differences, this work, coupled with our earlier 
discoveries of IgG-mediated trapping of viruses in both airway mucus and CVM,6,16 suggests IgG can 
reinforce the barrier properties of mucus at all major mucosal surfaces, supporting IgG-mucin 
crosslinking as a universal effector function of IgG at the first line of defense against pathogen invasion. 
This also implies that IgG-Fc is likely to bind to a target conserved feature among different mucins. Given 
that mucin is ~80% sugar by weight,31 it appears likely that IgG-mucin crosslinking is likely mediated by 
interactions between Fc N-glycans and glycans on mucins.  However, despite our observations, the 
precise number of pathogen-bound Abs required to sufficiently retard or immobilize pathogens within 
the mucus gel remains elusive. This is in part due to the complex biological nature of mucus, which 
contains shed epithelial cells, microbes, mucins, and other macromolecules such as AMPs.24,57,196  
Indeed, using fluorescence recovery after photobleaching (FRAP), we showed that in cell-free regions of 
CVM, IgG formed only weak, transient adhesive interactions with mucins, allowing individual Abs to 
rapidly diffuse through mucus to accumulate on invading pathogens;10 in contrast, IgG appeared to have 
higher affinity for cellular structures (cell debris, shed epithelial cells), markedly slowing its diffusion rate 
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through mucus. These observations imply that at any given time, antigen-specific Abs may be pathogen 
bound, freely diffusing, or cell-associated (Figure 6). 
Monoclonal antibodies are a highly effective class of biotherapeutics, typically administered via 
parenteral routes due to their instability in the GI tract. Nevertheless, oral administration of mAbs may 
be an effective tool to prevent enterobacterial infection.140–142 The most critical factor influencing 
successful passive immunization of the gut is delivery of sufficient quantities of active Ab, which can be 
influenced by gastric pH, protease activity, and GI residence time.140  Antibodies are gradually 
inactivated and degraded when exposed to gastric fluids containing proteolytic enzymes such as pepsin 
and elastase. 140,142 To overcome these unfavorable biochemical conditions, researchers are developing 
oral deliver formulations that preserve therapeutic mAb bioactivity.140,141,143  For instance, hydrogels 
encapsulating antibodies afforded greater mAb stability in the GI tract compared to mAb alone.140  
Several studies have shown that IgA is capable of arresting bacterial motility,70,149 due to their limited 
availability and propensity to immobilize pathogens by agglutination,38,124,197 we did not examine the 
ability of IgA anti-LPS to retard Salmonella mobility in mGIM. Moreover, in the context of translational 
development, IgG is currently the most widely used Ab isotype for biological applications.118,199  
While overcoming the chemical barriers of the GI tract may present a challenge, there are a 
number of advantages to oral Ab delivery.  Parenteral routes of administration require large doses of Ab 
to confer protection, making mAb therapies expensive and inaccessible.142 Oral dosage forms to treat 
local infections in the GI tract could have reduced cost due to reduced total quantities of mAb (by 
concentrating mAb directly at the site needed), as well as more relaxed sterility and formulation 
requirements for oral versus systemic administration. In addition, oral delivery minimizes the risks of 
serious adverse side effects.141  For conditions affecting the gut in particular, higher concentrations of 
systemic Ab are likely needed to achieve protective concentrations in GIM,141,151,199 thus increasing the 
risks of systemic side effects. We found that concentrations as low as 5 µg/mL anti-LPS  significantly 
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impacted the actively-moving population of bacteria in GIM.  At these concentrations, oral passive 
immunization may be a cost-effective and efficacious strategy to prevent/treat GI infections.20,136 
 
 
5.4 Methods and Materials  
 
5.4.1 Mice   
Animals were purchased from Jackson Laboratory (C57B/6J, Stock No. 000664; B6.129S7-Rag1, Stock No. 
002216).  Mice were bred and maintained at the University of North Carolina Chapel Hill animal facility. 
All mice were age and sex matched, and used between 8-10 weeks of age. All experiments were 
approved by University of North Carolina Institutional Animal Care and Use Committee (IACUC 15-327).    
 
5.4.2 GIM Collection.   
Mice were fasted for four hours to reduce the amount of luminal solid content in the GI tract before 
being sacrificed for mucus collection. The small intestine was excised and slit open length wise. To 
collect GIM, the smooth surface of a glass capillary pipette (Wiretrol®, Drummond Scientific) was used 
to gently scrape along GI tissue surface. Any remaining fecal-solids were separated and mGIM was kept 
in a microcentrifuge tube on ice or at 4°C until use within 24 hours200.  
 
5.4.3 Bacterial Strain and Growth Condition    
The bacterial strain used in this study was a non-chromosomally inserted green fluorescent protein 
(GFP)-expressing Salmonella typhimurium SL1344 (provided by Dr. Ed Miao at the University of North 
Carolina Chapel Hill). SL1344-pGFP was grown overnight at a shaking rate of 200 rpm at 37 °C in Luria-
Bertani (LB) broth supplemented with 50 µg/mL kanamycin for 14-16 hrs. Prior to microscopy, bacteria 
were diluted 1:10, and sub-cultured for an additional 2.5 hrs to ensure bacterial motility. Optical density 
(OD600) was measured using a NanoDrop One instrument from ThermoScientific. Bacterial motility in 




5.4.4 Sample Preparation for Particle Tracking Studies  
Mucus slides for particle tracking were prepared using a custom-made, 10 μL slide chamber.  Whole 
mucus was measured using a 20 μL glass capillary pipette. Five microliters of mGIM were transferred to 
the center of the slide chamber. Then, 2.5 μL of either mouse IgG1 anti-LPS (Virostat 6331; specific for 
Salmonella Typhimurium by whole cell ELISA) or mouse IgG1 anti-biotin (Vector Labs, MB-9100) were 
pipetted directly onto the surface of the mucus and mixed into the sample by gently stirring with a 
pipette tip to ensure uniform distribution. Next, 2.5 μL of motile Salmonella culture was added to the 
mixture and again gently stirred. The final Ab concentration in mucus was 5 ug/mL, based on the 
concentration of anti-LPS IgG which did not agglutinate Salmonella in mGIM, as well as the measured 
concentration of LPS-specific Ab in mGIM from wild-type mice (Supp. Fig. 1). A coverslip was used to seal 
the well without significant compression of the mucus surface, and quickly sealed with superglue to 
minimize sample dehydration. Prepared slides were incubated at 37°C for 15-30 minutes prior to 
imaging.  
 
5.4.5 Fluorescence Particle Tracking Microscopy.   
We used high resolution multiple particle tracking to record and quantify the motion of hundreds of 
individual fluorescent Salmonella typhimurium in mGIM. Specifically, the translational motions of the 
bacteria were recorded using an EMCCD camera (Evolve 512; Photometrics, Tucson, AZ) mounted on an 
inverted epifluorescence microscope (AxioObserver D1; Zeiss, Thornwood, NY), equipped with an Alpha 
Plan Apo 100x/1.46 NA objective, environmental (temperature and CO2) control chamber and an LED 
light source (Lumencor Light Engine DAPI/GFP/543/623/690). Videos (512 × 512, 16-bit image depth) 
were captured with MetaMorph imaging software (Molecular Devices, Sunnyvale, CA) at a temporal 
resolution of 66.7 ms and spatial resolution of 10 nm (nominal pixel resolution 0.156 μm/pixel) for 10 
s. At least five independent videos were captured per sample to ensure that bacteria were well-
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distributed over the entire surface. Trajectories of at least fifty individual bacteria were analyzed for 
each condition30. All experiments were performed at 37°C. 
 
5.4.6 Analysis of Salmonella motion.   
Image stacks acquired as described above were analyzed to extract the x and y positions of each 
Salmonella over time using a recently developed convolutional neural network187. Image stacks where 
directional drift of all particles was observed were excluded from analysis. This was determined visually 
by watching the time-lapse images and noting when all particles in the field moved in the same 
direction. To classify each increment of each track as either swimming, tumbling, or immobilized, we 
employed the widely-used Hidden Markov Model framework, with the Expectation-Maximization 
algorithm for all 190–193. We used a three-state Markov process to model the state-dependent motion of 
bacteria. The three motion states are swimming, where motion is directed with a random direction, 
tumbling, where motion is undirected and diffusive, and immobilized, where motion is also undirected 
and substantially hindered. We did not constrain the model to assign a smaller diffusion coefficient to 
the stuck state; nevertheless, the Maximum Likelihood stage of the Expectation-Maximization algorithm 
selected a diffusivity that was ~10 times less than the tumbling state (Table 1).  Motion in the swimming 
state was modeled as directed with a single speed magnitude and a three-dimensional random 
direction. The random direction was selected uniformly over the unit sphere upon each transition from 
the tumble state into the swimming state. In total, the model contained eight parameters: the swim 
speed, the three state-specific diffusion coefficients, and four transition rates controlling the stochastic 
dynamics of switching between the three motion states. Transitions were allowed bidirectionally 








5.4.7 Whole Salmonella ELISA to assess Anti-LPS Ab binding efficiency  
Salmonella was cultured as described above. In a 96-well half-area ELISA plate, sample wells were 
coated with 1 X 108 CFU in 100 µL of LB using the conversion factor: OD600 = 1 = 1 X 109 CFU/mL, 
followed by UV-inactivation for 1 hr and overnight incubation at 4°C. Plates were washed 5X with 0.05% 
PBS-Tween (PBST) and blocked with 170 µL of 5% milk in PBST for 1 hr at room temperature (RT). IgG1 
anti-LPS native (Virostat 6331) and IgG1-LPS deglycosylated were prepared at 250 ng/mL in 1% milk in 
PBST. Standard curves were prepared by two-fold serial dilution. Mouse anti-biotin IgG1 (Vector Labs, 
MB-9100) was used as an isotype control. Samples were incubated for 1 hr at RT, before being washed 
5X with 0.05% PBST. Secondary anti-mouse IgG1 (Santa Cruz, sc-2005) was diluted into 1% milk in PBST 
at 1:10,000 and 50 µL were added to each sample for 1 hr at RT. Plates were developed with TMB 
substrate was added (50 µL). The reaction was stopped with 50 µL of 2N H2SO4. Plates were read using a 
SpectraMax M2 plate reader at 450 and 570 nm (Molecular Devices). 
 
5.4.8 Enzymatic removal of Fc N-linked glycans using PNGase F 
Fc-glycans were removed from IgG anti-LPS following the manufacturer's standard protocol for Peptide 
N-Glycosidase F (PNGase F, Sigma P7367). Briefly, Ab solutions for deglycosylation were prepared by 
buffer exchanging 200 µg of IgG1-anti LPS (Virostat 6331) into 20 mM ammonium carbonate. Denaturing 
solution was added and the sample was heated to 100 °C for 10 minutes. After cooling, 20 µL of Triton 
X-100 (Sigma 93443) was added, and the sample was gently mixed. Prepared PNGase F was added to the 
reaction mixture and incubated at 37 °C for 1-3 hrs. The reaction was stopped by heating the sample to 
100 °C for 5 minutes, then placed on ice to stop further enzymatic digestion. Sample was then buffer 
exchanged into sterile PBS using a 50K MWCO filter  (Millipore-Sigma UFC505008). Flow through was 
analyzed by SDS-PAGE. Ab concentration was measured using a NanoDrop One instrument 




5.4.9 SDS-PAGE and Western Lectin Blot to validate Fc N-glycan removal 
Protein samples (5 µg) were prepared for SDS-PAGE by diluting in ultrapure water and mixing with 4X 
protein sample buffer (Invitrogen NP0007) and 1 uL dithithreitol (Sigma 43816). Samples were heated at 
70 °C for ten minutes and resolved by SDS-PAGE. Native anti-LPS IgG1 and human intravenous 
immunoglobulin (IVIg, Privigen NDC 442-6-437-10) were included as positive glycosylation controls. Two 
gels were run simultaneously for silver stain (Pierce Silverstain kit, ThermoScientific 24612) and lectin 
blotting. Proteins were transferred from the gel to a nitrocellulose membrane using a Novex® Semi-Dry 
blotting apparatus at 20 V for 45 minutes (ThermoScientific SD1000). The membrane was rinsed several 
times with 0.1% PBST and blocked with 1X Carbo-Free™ Blocking Solution (Vector Labs SP-5040) and for 
1hr at RT. Biotinylated, mannose-specific Concanavalin A lectin (ConA) was added to the membrane at a 
concentration of 2 µg/mL in PBS and incubated overnight at 4 °C with rocking (Vector Labs B-1005). 
After washing, anti-biotin HRP (Vector Labs SP3010) was added to the membrane at a 1:10,000 dilution 
in 0.1% PBST for 1 hr at RT. Bio-Rad ECL reagent (Bio-Rad 107060) was used to develop the blot 
according to manufacturer’s instructions.   
 
5.4.10 Transwell assay to evaluate Salmonella penetration across mucus 
Mouse gastrointestinal mucus was collected as described above; approximately 160 – 200 µL of GIM 
was collected from each mouse. Salmonella was cultured to motility as described. A wiretrol applicator 
was used to transfer 40 µL of mucus per sample were transferred to a 96-well, polycarbonate 
membrane transwell plate with 8 µM pore size (Corning 3374). Next, 150 µL of kanamycin-containing LB 
(50 µg/mL) was pipetted into the bottom transwell compartment. Abs were prepared at 50 µg/mL to 
account for a 10-fold dilution. Five microliters Ab were added to each sample, followed by 5 µL of 
bacteria, then mixed gently. Where Ab was not added, 5 µL of buffer was added instead. Where bacteria 
were not added, 10 µL LB was added to maintain the similar dilutions across samples. Transwell plates 
were incubated at 37 °C for 4 hours in the absence of CO2. Bacterial growth and transit from the mucus-
 
96 
containing transwell to the receiver plate was followed over time by measuring OD600 at 30 minute 
intervals using a SpectraMax M2 plate reader (Molecular Devices).  
 
5.4.11  Mouse IgG1 Fab preparation and purification   
Mouse IgG1-Fab was prepared from IgG1 anti-LPS (Virostat 6331) using the Pierce Mouse IgG1 Fab and 
F(ab ́)2 Preparation Kit according to manufacturer’s instructions (Thermo Scientific 44980). Briefly, ficin 
resin was equilibrated and 150 µg of IgG1 anti-LPS were prepared using a Zeba Spin desalting column. 
The prepared IgG sample (500 µL) was added to the immobilized ficin column. Digestion proceeded for 4 
hours in an end-over-end mixer at 37 °C. Next, the spin column was centrifuged to separate digest from 
immobilized ficin resin. Resin was washed three times with 0.5 mL of Protein A binding buffer. Wash and 
digest fractions were combined to yield a total volume of 2 mL. After equilibration of the Nab Protein A 
column, digested Ab was added to the column. Protein A resin and sample were incubated at RT for 10 
minutes with end-over-end mixing, before centrifugation to collect Fab fragments. Protein 
concentration was estimated by measuring the absorbance at 280 nm on a nanodrop.  
 
5.4.12 Extracellular Growth Assay  
Kanamycin-resistant Salmonella Typhimurium was cultured to an optical density of 0.6 (late-log phase) 
as described above. The bacterial culture was then diluted 1:20 into fresh LB media containing 50 ug/mL 
kanamycin and 20 uL per well dispensed into different tubes containing varying concentrations of anti-
LPS native, anti-LPS Fab, or non-specific Ab control in LB media. After thorough mixing, bacterial samples 
(total volume 200 uL) were dispensed into a sterile 96-well plate (Costar 3599) with three to five 
replicates per Ab concentration. Plates were placed at 37 C without CO2. Bacterial growth was 
monitored spectrophotometrically using SpectraMax M2 microplate reader at a wavelength of 600 nm, 
with readings taken every 30 minutes over 4 hours. Since the molecular weight (MW) of the Ab Fab 
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region is ~50 kDa, or one third the MW of a full-length Ab, total protein concentration was decreased by 
one-third to maintain the same molar ratio of Fab binding sites using Fab alone versus full length Ab.   
 
5.4.13 Statistical Analysis  
Results were analyzed with one-way or two-way ANOVA with Tukey’s or Sidak’s post-test, respectively.  
Student’s paired t-test were used as appropriate using Prism (GraphPad) software. Differences between 
groups were considered significant at p<0.05. All error bars represent SD. 
 
 k1 k2 k3 k4 Swim 
Speed 
No Exogenous Ab 0.57 0.49 0.37 1.2 18.7 
IgG anti-biotin 0.61 0.47 0.37 1.3 18.1 
IgG anti-LPS 0.56 0.50 0.25 2.4 15.3 
IgG anti-LPS degly 0.57 0.48 0.39 1.3 18.6 
 






Figure 5.1: Anti-LPS IgG alters the nature of Salmonella motility in mouse GIM.   
(A) Representative traces of the three mobility states over thirty consecutive frames: immobilized, 
hindered/diffusive and swimming. (B) Box plots displaying the percent of total trace increments that are 
classified as immobilized,  hindered, or swimming  in the presence of either 5 µg/mL IgG1 anti-biotin or 5 
µg/mL IgG1 anti-LPS. (C) Average rate of transition of an individual Salmonella from the hindered to 
swim motion state and (D) average rate of transition of an individual bacterium out of the swim to the 
hindered motion state in the presence of either 5 µg/mL IgG1 anti-Biotin or 5 µg/mL IgG1 anti-LPS.  Data 
presented as mean, min, max. Two-Way ANOVA with Sidak’s multiple comparison’s test and Student’s 






Figure 5.2: LPS-specific IgG decreases the amount of time Salmonella spend swimming in GIM.  
(A) Percent of traces where bacteria undergo swimming for at least five consecutive frames, (B) percent 
of time spent in the swim state by bacteria undergoing extended swimming motion, and (C) average 
swim velocity of all swimming increments in the consecutively swimming bacterial population in the 
presence of either 5 µg/mL IgG1 anti-Biotin or 5 µg/mL IgG1 anti-LPS. (N=18). Data presented as mean, 
















Figure 5.3: Antibody-mediated trapping of Salmonella in mGIM is dependent upon the Ab N-linked, 
Fc-glycan. (A) SDS-PAGE gel and concanavalin A western-lectin (specific for high-mannose structures) 
showing successful deglycosylation of IgG1 anti-LPS, indicated by a shift in size and negative lectin signal. 
(B) Whole cell ELISA comparing antibody binding of IgG1 anti-LPS native and anti-IgG1 LPS 
deglycosylated to Salmonella demonstrate that Ab deglycosylation does not impair binding to 
Salmonella.  (C) Box plot displaying the percent of total trace increments in the swimming state, (D) 
percent of traces where bacteria undergo swimming for at least five consecutive frames, 
 (E) percent of time spent in the swim state by bacteria undergoing extended swimming motion, and (F) 
average swim velocity of all swimming increments in the consecutively swimming bacterial population in 
the presence of either 5 µg/mL IgG1 anti-Biotin or 5 µg/mL IgG1 anti-LPS. Data presented as mean, min, 












Figure 5.4: Simulated first-passage time (FPT) analysis of Salmonella penetration across mouse 
gastrointestinal mucus of varying thickness. (A) FPT analysis displaying the fraction of Salmonella 
capable of penetrating a mGIM layer of thicknesses 0 – 1000 µm over five hours in the presence of (A)  






















Figure 5.5: Salmonella penetration across mouse gastrointestinal mucus ex vivo. 
(A) Schematic of transwell assay to evaluate Salmonella penetration across mGIM ex vivo in the 
presence or absence of IgG1 anti-biotin, IgG1 anti-LPS native, or IgG1 anti-LPS deglycosylated (5 µg/mL). 
(B) Optical density (OD600) of Salmonella penetration across mGIM in the presence of specific or non-
specific antibody at 5 µg/mL. (C) Dose effect of native IgG1-LPS antibody (0 – 10 µg/mL) in blocking 
Salmonella penetration across mGIM ex vivo. (D) Extracellular growth assay showing optical density of 
bacterial cultures in the presence of increasing concentrations of anti-LPS IgG Fab to show that Antigen-
specific Ab binding to Salmonella is non-bactericidal. (E) Transwell assay with increasing concentrations 
of anti-LPS IgG Fab shows that Ab-binding alone does not prevent bacterial translocation across mGIM. 
Data shown represents Salmonella growth at four hours. Mean ± SD. One-way ANOVA with Tukey’s 






Figure 5.6: Proposed schematic of Ab-mediated trapping of Salmonella in mGIM. (A) In the absence of 
specific Ab, pathogens remain in their native state, swimming with active motion, or in an undirected 
state. (B) Abs accumulate on the pathogen surface to eventually yield sufficient avidity to immobilize 






























Figure 5.7 (Supp.Fig.1): Quantification of LPS-specific Antibody in WT GIM supernatant. Average total 
levels of LPS-specific Ab in wild-type mouse GIM, determined using whole-bacterial cell based ELISA, was 




















Figure 5.8 (Supp.Fig.2): Non-specific IgG anti-biotin (Control mAb) does not alter Salmonella mobility 
in mGIM. (A) Box-whisker plots displaying the percent of total trace increments classified as 
immobilized,  hindered, or  swimming  without exogenous antibody added (No mAb) or in the presence 
of 5 µg/mL IgG1 anti-biotin. (B) Average rate of transition of an individual Salmonella from the hindered 
to swim motion state and (C) swim to the hindered motion state in the presence of either 5 µg/mL IgG1 
anti-biotin or without exogenous antibody (no mAb). Data presented as mean, min, max. Two-Way 














Figure 5.9 (Supp.Fig.3): LPS-specific IgG does not impact the transition rates of bacteria between the 
stuck and tumble motion-states.  (A) Average rate of transition of an individual Salmonella from the (A) 
stuck to hindered motion state, (B) swim to the hindered motion state, (C) hindered to swim motion 
state and (D) swim to the hindered motion state in the presence of either IgG1 anti-biotin, native IgG1 
anti-LPS, or deglycosylated IgG1 anti-LPS at 5 µg/mL. Data presented as mean, min, max. One-way 











CHAPTER 6: CONCLUSIONS AND PERSPECTIVES 
 
 
In this dissertation, I systematically investigated the interactions between antigen-specific Abs 
against either HSV-1 or Salmonella and mucus gels of two distinct secreted mucin types (MUC5B and 
MUC2).  Despite the abundance of Abs in mucus,11,12  due to the seemingly negligible affinity between 
individual Ab molecules and mucins,7–10 the use of Abs to reinforce the diffusional barrier properties of 
mucus was long overlooked. Unlike other Ab-effector functions that rely on interactions with specific 
receptors or proteins to be activated, we have found the interaction of Abs and mucus to be relatively 
non-specific, potentially mediated by interactions between Fc-glycans and charged carbohydrate sugars, 
which are broadly conserved across a number of biopolymeric matrices.13 In contrast to other mucosal 
sites throughout the body where sIgA is abundant,38  Ag-specific antibodies in the vagina are 
predominantly IgG;37,89  with limited capacity for agglutination. The results of these studies challenge the 
dogma that IgA is the only Ab capable of limiting bacterial or virus passage through mucus, and that 
agglutination is required for such “immune exclusion.”130 An improved understanding of mucosal 
immune protection, mediated by Ab-mucin interactions, provides a new perspective of host-pathogen 
interactions that suggests the relatively non-specific biochemistry and microstructure of mucus can be 
fortified with specific Abs, including IgG, to protect against a diverse spectrum of pathogens. These 
insights can be applied to enhance Ab-based prophylactic strategies against mucosally-transmitted 
pathogens. For instance, rather than relying on high titers of neutralizing IgG in systemic circulation, 
local passive immunization with both neutralizing and non-neutralizing Abs (both sIgA and IgG) may limit 




Reinforcing the CVM barrier to trap pathogens in mucus thus represents an obvious strategy to 
prevent STIs. Given the effects of microbiota and both exogenous and endogenous hormones on 
CVM,46,94,95 it was critical to ensure that IgG-mucin interactions were consistently potent across a vast 
diversity of specimens. We found that the muco-trapping function of anti-HSV-IgG against HSV-1 was 
conserved across the menstrual cycle and in specimens with G.vaginalis-dominant microbiota. While 
dysbiosis of the vaginal microbiome has been associated with increased susceptibility to infection and 
enhanced viral replication,72,110  this is one of the first studies to evaluate the influence of specific 
microbial communities on effector functions of IgG.92,93 Although we did not directly measure it, the 
viscosity of CVM in CST-IV classified samples was likely lower compared to CVM from other CST types 
due to secretion of sialidases by G.vaginalis.44 The consistency of Ab-mediated trapping in these 
samples, as well as in those collected during the “window of vulnerability,” when mucus viscosity is also 
decreased to permit sperm penetration, 107 suggests that Ab-mucin interactions may by nature have 
evolved to be independent of the microrheological properties of the mucus gel. These observations, 
coupled with the hormone-induced variability in transcytosis of IgG from systemic circulation to the 
vaginal epithelium by FcRn,80,90 underscore the likely physiological importance of this protective 
mechanism of IgG, and highlight passive immunization as a viable strategy to protect against STIs. 
Variable antibody responses can be induced by active vaccination strategies against sexually 
transmitted viruses depending on age, hormonal status, and immunocompetency.11,105  Passive 
immunization with high affinity and/or neutralizing antibodies directly to the vaginal mucosal barrier 
ensures uniform protective Ab concentrations across all subjects. Identification of the most potent Ab 
isotype and subclass that consistently trapped HSV virions in CVM was a critical step toward preclinical 
translational of Ab-mucin interactions. Thus, I tested Ab-mediated trapping potency of HSV-1 by six 
different subclasses of mAbs with Fab sequences targeting the same HSV-1 gD epitope, and concluded 
that IgG1-based Ab constructs would be most suitable for vaginal passive immunization. Recent success 
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of clinical studies demonstrating the safety of vaginally delivered IgG1 179 and that release of anti-HIV 
IgG1 mAbs from vaginal rings sustained protective Ab levels in the vagina of rhesus macaques for >21 
days179  further supports the use of IgG1 for vaginal-mucosal applications. Additionally, the 21-day half-
life of IgG1 may be matched to the monthly schedule of injectable or oral contraceptives and is longer 
than currently used antiviral drugs.171  Finally, while Ab-mucin interactions should not preclude other 
effector functions of IgG1, HSV evasion strategies, such as the production of molecules that interfere 
with complement and ADCC functions mediated by IgG1, may not be relevant to trapping in 
cervicovaginal mucus, where FcR-bearing cells are localized beneath the epithelium and complement 
activity is limited.74   
Finally, I showed that Ab-mucin interactions were capable of retarding the motility of highly 
motile Salmonella in GIM, a mucosal surface that is predominantly composed of secreted mucin type 2 
compared to MUC5-dominated CVM.45 This study provided further evidence that the interaction 
between Abs and mucins to reinforce mucosal surfaces may indeed have evolved to be biochemically 
non-specific. Indeed, secretory component (SC), tightly bound to the Fc-region of IgA to confer the 
dimeric form of sIgA, has seven potential N-linked glycosylation sites.201 In the absence of these 
carbohydrates, sIgA fails to associate with mucus and prevent infection,42 substantiating the importance 
of glycans in maintaining sIgA-mucin interactions. As the favored antibody for retention in the acidic 
environment of the FRT,117 it is thus highly likely that IgG-associated N-glycans play a similar role.  
While the precise molecular mechanism of the interactions between Abs and mucins is 
unknown, the findings of this dissertation provide a basis for engineering the next generation of either 








1) Investigation of muco-trapping potency of IgG1 with different Fc-glycosylation patterns.  
 
Similar to other IgG effector functions, IgG-mucin interactions appear to be mediated by N-glycans 
on IgG-Fc. We have received fully characterized HSV8 IgG1 Abs with predominantly GnGn, Gal, or 
Aglycosylated N-glycan profiles from Mapp Biopharmaceutical. In pilot studies, HSV8-GnGn (lacking 
terminal galactose or sialic acid) exhibited comparable trapping potency to HSV8 produced in HEK293 
cells. In contrast, HSV8-Gal, with terminal galactose residues, markedly abrogated the IgG-mucin affinity 
to the same extent as HSV8 without N-glycans (HSV8-Agly). These preliminary results underscore the 
intricacies of the glycan-dependent IgG-mucin interaction.   
 
2) Engineering the IgG-Fc to optimize potency Ab-mediated tethering of pathogens to mucus 
Prior studies in mucus have demonstrated that IgM traps more potently than IgG.4 Further 
computational analyses have determined that there exists an optimal alpha, or rate at which an 
antibody diffuses through mucus, for trapping to occur.7,8,13 The alpha is ~0.2, which is stronger than 
that of IgM (~0.5) but weaker than a biotin-avidin interaction (~0).8 An alpha value of ~0.2 allows for 
unbound Abs to easily diffuse through mucus, but when several Abs bind to the same Ag, the increased 
avidity to the mucin mesh results in effective trapping. Using biochemical features of IgM as a model, 
IgG Abs are being reengineered to incorporate additional N-linked glycosylation sites  (IgM has 51 vs. 
IgG’s 2), secretory-component association sites, and an additional Fc-region (IgM is pentameric)202.  
 
3) Probing specific molecular interactions between Abs and complex biological hydrogels.  
 
A number of biological hydrogels (or components thereof) are commercially available. By gelling 
polymeric disaccharides that each contain a single functional group of interest, we can isolate which 
groups are capable of participating in Ab-mediated interactions. This will allow for de novo construction 
of a biogel capable Ab-mediated trapping without prior knowledge of the desired antigenic target. 
Potential uses include coverings for second- and third-degree burns, in which hydrogels are employed to 
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keep the wound hydrated but infection is common. This population is especially at risk of contracting 
infection; with the rise of antibiotic resistance preventative Abs in wound dressings would be beneficial.  
To date, we have probed interactions of IgG and IgM with agarose (only -OH), alginate (-COOH), chitosan 
(-NH2), and carrageenan (-SO3), as well as basement membrane, laminin, and collagen. Both basement 
membrane and laminin participate in IgG- and IgM-mediated trapping in a dose-dependent manner, 
though IgM-mediated trapping is more potent. Collagen, which contains ample -NH2 groups but lacks -
COOH functional groups, participates in IgM- but not IgG-mediated trapping. In agarose (-OH) IgM-
mediated trapping is present, but very weak, and IgG-mediated trapping is not observed. Finally, 
alginate (COOH) moderately participates in IgG-mediated trapping, while IgM-mediated trapping is 
strong. 
 
4) Understanding the rheological properties of hydrogels that influence Ab-mediated trapping  
 
Using a subset of the various biogels described above, we have used cone and plate rheometry to 
test their response to an oscillating shear stress. From this, we can measure a) the viscous modulus (i.e. 
how “liquid” a gel is), 2) the elastic modulus (i.e. how “solid” a gel is), 3) ratio of viscous modulus/elastic 
modulus (i.e. tan delta), and 4) complex viscosity. True gels have a tan delta between 0.06-0.2. 
Preliminary results have shown that there is no correlation between trapping capacity of a specific 
biogel and viscosity.  
 
5) Elucidation of the number of Ag-specific Abs required for efficient virus trapping in CVM  
 
We have observed that mAbs against HIV-1, including broadly-neutralizing VRCO1 against the 
envelope glycoprotein gp120, can consistently immobilize HIV-1 in a subset of CVM from women 
(unpublished results). A report by Zhu et.al., which used cryo-electron microscopy to investigate the 
surface features of HIV-1 virions, determined that the number of Env spikes on the surface of an HIV 
virion is 14±7.203 Significantly, this suggests that as few as tens of Abs bound to a virion surface can 
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retard its motion in CVM. To validate this, we are employing click-chemistry to link Fc-fragments isolated 
from human IVIg to PEGylated nanoparticles. Using a flash-nanoprecipitation method, particle size and 
the number of Fc-conjugates can be tightly controlled. As the number of N-glycan-containing Fc-
fragments on the PEG particle surface increases, readily diffusive, mucus-penetrating PEG particles4 
should become decreasingly mobile in CVM.  
Completion of these studies will yield a comprehensive analysis of the biochemical and biophysical 
parameters governing Ab-mucin interactions, paving the way toward a multitude of therapeutic 
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